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Members	   of	   the	   transforming	   growth	   factor	   (TGF)-­‐β	   family	   exert	   their	   effect	   on	  
virtually	  all	  cell	  types	  in	  the	  body,	  producing	  diverse	  and	  complex	  cellular	  responses.	  
Additionally,	   TGF-­‐β	   signaling	   is	   deregulated	   and	   hyperactive	   in	   many	   malignant	  
conditions,	   making	   it	   an	   appealing	   target	   in	   the	   combat	   of	   cancer	   disease.	   The	  
predominantly	  endothelial	   TGF-­‐β	   receptors,	  ALK1	  and	  endoglin,	  which	  are	  activated	  
during	  neoangiogenesis	  both	  during	  development	   and	  pathological	   conditions,	   pose	  
attractive	   modulating	   opportunities	   to	   impair	   tumor	   vessel	   formation	   and	   cancer	  
progression.	   However,	   the	   precise	   function	   of	   TGF-­‐β	   family	   signaling	   in	   endothelial	  
cells	  is	  difficult	  to	  predict,	  as	  it	  appears	  highly	  context	  dependent	  due	  to	  a	  myriad	  of	  
ligands	  and	  receptors	  influencing	  the	  final	  outcome.	  Furthermore,	  TGF-­‐β	  is	  involved	  in	  
autocrine	  and	  intricate	  dynamic	  paracrine	  signaling	  events	  in	  the	  context	  of	  the	  tumor	  
microenvironment.	   Pharmacological	   inhibitors	   for	   ALK1	   and	   endoglin	   have	   been	  
developed	  and	  will	  facilitate	  more	  comprehensive	  studies	  on	  the	  exact	  function	  of	  the	  
TGF-­‐β	  family	   in	  the	  tumor-­‐associated	  endothelium.	  Here,	  we	  summarize	  the	  current	  
knowledge	  on	  TGF-­‐β	  signaling	  in	  the	  regulation	  of	  the	  vascular	  network	  as	  alternative	  
targets	  to	  VEGF	  and	  incorporate	  our	  novel	  and	  promising	  findings	  in	  the	  field.	  Our	  two	  
studies	   aiming	   at	   dissecting	   the	   independent	   role	   of	   ALK1	   and	   endoglin	   resulted	   in	  
very	  distinctive	  outcomes.	  While	  ALK1	  suppression	  results	  in	  sustained	  tumor	  growth	  
by	  affecting	   the	   tumor	  neovasculature,	   endoglin	   impairment	   generates	   a	  weakened	  
and	  increasingly	  lenient	  vasculature	  to	  the	  passage	  of	  malignant	  cells	  to	  and	  from	  the	  
bloodstream.	  Our	  both	  seemingly	  contradictory	  studies	  challenge	  the	  current	  view	  of	  
a	  strong	  interconnection	  between	  ALK1	  and	  endoglin	  in	  the	  vasculature.	  
The	   ongoing	   clinical	   trials	   of	   inhibitors	   affecting	   ALK1	   and	   endoglin	   involvement	   in	  
vascular	   formation	   during	   malignant	   progression	   will	   further	   clarify	   the	   valuable	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1. INTRODUCTION	  
1.1.	  Cancer	  therapies	  targeting	  the	  tumor	  endothelium	  
	  
The	   cardiovascular	   system	   is	   the	   first	   organ	   system	   to	   form	   and	   function	   during	  
embryogenesis	  (1).	  The	  development	  of	  an	  efficient	  system	  to	  conduct	  nutrients	  and	  
oxygen	   is	   primordial	   for	   supplying	   the	   metabolic	   needs	   of	   a	   rapidly	   developing	  
embryo.	  The	  organization	  of	  the	  vascular	  tree	  and	  the	  timing	  of	  its	  genesis	  are	  highly	  
preserved	  and	  tightly	  regulated	  among	  species.	  The	  relevance	  of	  such	  preservation	  is	  
highlighted	  by	  the	  fact	  that	  the	  vascular	  network	  does	  not	  simply	  provide	  metabolic	  
sustenance,	   but	   also	   supplies	   crucial	   signaling	   cues	   required	   to	   orchestrate	  
differentiation	   and	   development	   of	   other	   organs	   during	   embryogenesis	   (2).	   To	   this	  
respect,	   as	   the	  developing	  vasculature	   in	   the	  embryo	   is	   required	   for	  organogenesis,	  
the	  neovasculature	  formation	  in	  a	  tumor	  is	  preponderant	  to	  the	  onset,	  maintenance	  
and	  progression	  of	  neoplastic	  disease.	  	  
In	   adulthood,	   proangiogenic	   and	   antiangiogenic	   signaling	   molecules	   are	   in	  
homeostatic	  balance	  (3,	  4).	  Formation	  and	  growth	  of	  new	  vessels	   is	  therefore	  under	  
strict	   control.	   The	   recruitment	   of	   the	   vasculature	   or	   activation	   of	   angiogenesis,	   a	  
process	   termed	   the	   angiogenic	   switch,	   is	   a	   necessary	   condition	   for	   tumor	  
development	   and	   progression	   in	   most	   solid	   tumor	   types	   (3,	   4).	   An	   expanding	  
malignant	  cell	  conglomerate,	   like	  any	  other	   tissue	   in	   the	  body,	   requires	  provision	  of	  
oxygen	   and	   nutrients	   to	   thrive	   under	   hypoxic	   conditions	   and	   ultimately	   survive.	  
Additionally,	   further	   recruitment	  of	   cells	   to	   the	   tumor	  microenvironment	  mimics	   to	  





Figure	  1.	  The	  tumor	  microenvironment	  as	  a	  multicellular	  organ	  with	  some	  of	  its	  classical	  components:	  	  
aberrant	   tumor	   cells,	   endothelial	   cells,	   pericytes	   or	   mural	   cells,	   cancer-­‐associated	   fibroblasts	   and	  
immune	  cells,	  such	  as	  macrophages	  and	  lymphocytes.	  
	  
	  	  4	  
The	  formation	  of	  new	  blood	  vessels	  in	  pathological	  processes,	  such	  as	  cancer,	  leads	  to	  
unstable,	   proliferative	   and	   sub-­‐optimally	   functional	   vessels	   in	   a	   dynamic	   state	   of	  
remodelling	  (5).	  Tumor	  vascular	  networks	  support	  tumor	  growth,	  in	  spite	  of	  a	  range	  of	  
abnormal	   features	   that	   compromise	   their	   physiology.	   Tumor	   vessels	   are	   commonly	  
tortuous	  and	  leaky,	  causing	  hemorrhage	  and	  increased	  interstitial	  fluid	  pressure	  (5,	  8-­‐
10).	   Inefficient	  blood	   flow	  caused	  by	  poor	  hierarchical	   anatomy	  and	  organization	  of	  
the	   tumor	   vasculature	   leads	   to	   ischemia	   and	   necrosis,	   which	   are	   common	  
characteristics	  of	  rapidly	  growing	  tumors.	  	  
These	  underdeveloped	  properties	  of	   tumor	  vessels	  would	  presumably	   contribute	   to	  
increased	   sensitivity	   and	   efficacy	   of	   antiangiogenic	   drugs	   (11).	   On	   one	   hand,	   the	  
tumors’	  critical	  dependency	  on	  a	  functional	  actively	  growing	  vasculature	  to	  support	  its	  
malignant	  progression	  and	   tumor	   cell	   dissemination,	   and	  on	   the	  other	  hand,	   tumor	  
cell	  instability	  and	  aberrant	  physiology,	  strongly	  highlights	  tumor	  vasculature	  targeting	  
approaches	   as	   attractive	   alternative	   strategies	   for	   cancer	  management.	  Aiming	   at	   a	  
component	   of	   the	   tumor	   distinct	   to	   that	   contemplated	   by	   conventional	   cytotoxic	  
drugs,	  further	  offers	  the	  possibility	  of	  significant	  complimentary	  antitumor	  efficacy.	  
Based	   on	   several	   successful	   preclinical	   studies,	   the	   oncologic	   clinical	   field	   held	   high	  
expectations	  on	  the	  use	  of	  antiangiogenic	  therapies	  to	  combat	  cancer.	  Rooted	  in	  the	  
belief	   that	   vascular	   endothelial	   growth	   factor	   (VEGF)	   and	   its	   receptors,	   vascular	  
endothelial	   growth	   factor	   receptors	   (VEGFRs),	   played	   a	   central	   role	   in	   angiogenesis	  
(12),	   it	   was	   expected	   that	   blocking	   the	   VEGF	   pathway	   would	   eradicate	   the	   tumor	  
vasculature	  and	  cancer	  disease	  would	  hence	  be	  eliminated.	  	  The	  introduction	  of	  VEGF-­‐
targeting	   drugs	   in	   cancer	   treatment	   generated	   modest	   clinical	   benefit	   in	   multiple	  
cancer	   patients	   rendering	   prolonged	   progression-­‐free-­‐survival	   and	   overall	   survival	  
measured	   only	   in	   months,	   and	   mostly	   in	   combination	   with	   standard	   care	  
chemotherapy	   (13).	   In	   summary,	   VEGF-­‐targeting	   agents	   are	   failing	   to	   produce	  
enduring	  clinical	  responses	   in	  most	  patients	  (14)	  even	   in	  combination	  with	  cytotoxic	  
agents,	  not	  conveying	  the	  expected	  persistent	  cure	  (15-­‐18).	  
	  
Recent	   studies	   provide	   evidence	   for	   inhibition	   of	   primary	   tumor	   growth	   by	   using	  
VEGF-­‐inhibiting	  strategies;	  however	  they	  lead	  to	  a	  decrease	  in	  mouse	  survival	  due	  to	  
increased	   invasiveness	   and	   metastasis	   dissemination	   (19-­‐21).	   These	   seemingly	  
paradoxical	   results	  may	   help	   understand	  why	   the	   clinical	   efficacy	   of	   these	   drugs	   is	  
comparatively	  poor	  in	  patients.	  However,	  a	  number	  of	  questions	  were	  raised	  based	  on	  
these	  new	  observations.	  The	  main	  concern	  in	  the	  field	  regards	  the	  legitimacy	  of	  using	  
VEGF-­‐targeting	  drugs	   if	   they	  accelerate	   the	  disease	  progression	   rate	   into	  metastatic	  
late	  stage	  disease,	  with	  metastasis	  being	  the	  eventual	  cause	  of	  death	  for	  most	  cancer	  
patients	  (22).	  
The	   development	   of	   resistance	   and	   acquisition	   of	   a	   more	   aggressive	   and	   invasive	  
phenotype	  in	  tumors	  that	  have	  been	  treated	  with	  VEGF	  neutralizing	  approaches	  thus	  
points	  towards	  the	  need	  for	  additional	  extensive	  examination	  of	  the	  biology	  of	  tumor-­‐
nurturing	   blood	   vessels,	   in	   order	   to	   more	   accurately	   pinpoint	   promising	   and	   novel	  
antiangiogenic	  targets.	  It	  is	  though	  expected	  that	  curing	  cancer	  is	  a	  complex	  task	  that	  
requires	   a	   combined	   effort	   of	   utilizing	   various	   strategic	   angles	   targeting	   different	  
tumor	  cellular	  compartments,	  in	  addition	  to	  aiming	  at	  the	  ample	  spectrum	  of	  signaling	  
networks	  that	  are	  commonly	  deregulated	  in	  malignant	  cells.	  
Often	  altered	  in	  neoplasms	  and	  involved	  in	  multiple	  cellular	  functions,	  the	  large	  TGF-­‐β	  
family	  is,	  as	  a	  result,	  an	  obvious	  candidate	  for	  directing	  such	  efforts.	  More	  specifically,	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because	  TGF-­‐β	  signaling	  encompasses	  a	  number	  of	  vascular	  restricted	  receptors,	  they	  
represent	  attractive	  antiangiogenic	  therapeutic	  targets	  in	  cancer.	  	  
	  
1.2.	  The	  TGF-­‐β-­‐rich	  tumor	  microenvironment	  
The	  tumor	  microenvironment,	  or	  stroma,	  influences	  the	  growth	  of	  the	  tumor	  and	  its	  
ability	  to	  progress	  and	  metastasize.	  The	  stroma	  thus	  constitutes	  an	  important	  aspect	  
to	  consider	  when	  developing	  therapeutic	  approaches,	  as	  it	  can	  change	  interstitial	  fluid	  
pressure,	  limit	  the	  access	  of	  therapeutics	  to	  the	  tumor,	  alter	  drug	  metabolism	  or	  even	  
contribute	  to	  the	  development	  of	  drug	  resistance	  (7).	  
Despite	   the	   importance	   of	   tumor-­‐host	   stroma	   interactions,	   there	   is	   limited	  
understanding	  of	  the	  stromal	  milieu	  composition,	  and	  the	  complexity	  and	  dynamics	  in	  
the	   relationship	   between	   the	   tumor	  malignant	   cells	   and	   the	   surrounding	   host	   cells	  
(23-­‐25).	  It	  is,	  however,	  nowadays	  acknowledged	  that	  tumor	  cells	  and	  their	  stroma	  co-­‐
evolve	  during	  tumorigenesis	  and	  progression	  (24).	  Nonetheless,	  the	  precise	  nature	  of	  
the	   cells	   that	   comprise	   the	   normal	   and	   tumor	   stromas,	   how	   the	   cells	   within	   the	  
stroma	  or	  newly	  recruited	  cells	  are	  altered	  during	  tumor	  progression,	  and	  how	  they	  
reciprocally	   exert	   influence	   on	   tumor	   initiation	   and	   progression	   is	   still	   poorly	  
understood	   (24).	   	   Interestingly,	   stromal	   elements	   seem	   to	   play	   a	  more	  pronounced	  
supportive	  role	  in	  late	  stages	  of	  cancer	  disease	  (7).	  
The	   large	   family	   of	   TGF-­‐β	   extracellular	   pleiotropic	   cytokines	   exerts	   influence	  
essentially	   on	   all	   cellular	   strata	   in	   the	   body,	   namely	   in	   epithelial	   cells,	   fibroblasts,	  
immune,	  endothelial,	   lymphatic	  and	  perivascular	  cells	   (26).	  TGF-­‐β	   is	   the	  prototypical	  
element	  of	  an	  extensive	  ligand	  group	  that	  also	  includes	  bone	  morphogenetic	  proteins	  
(BMPs),	   activins,	   inhibins,	   Nodal	   and	   growth	   and	   differentiation	   factors	   (GDFs)	   that	  
elicit	  signaling	  activity	  through	  a	  collection	  of	  five	  type	  II	  receptors	  (TGF-­‐βRII,	  BMPRII,	  
ActRIIa,	  ActRIIb,	  AMHRII)	  and	  seven	  type	  I	  serine/threonine	  kinase	  receptors	  (ALK1-­‐7)	  
(27).	   Different	   ligand-­‐receptor	   II-­‐receptor	   I	   combinations	   can	   be	   assembled,	  
delineating	  one	  of	  the	  TGF-­‐β	  family	  hallmarks	  of	  complexity.	  
In	   normal,	   unstressed	   tissue,	   sustained	   basal	   release	   of	   TGF-­‐β	   by	   local	   sources	  
regulates	   homeostasis.	   In	   pathological	   conditions,	   TGF-­‐β	   is	   abundantly	   released	   in	  
the	  tumor	  microenvironment,	  initially	  as	  a	  signal	  to	  avoid	  premalignant	  progression,	  
but	  eventually	  as	  a	  cue	  that	  cancer	  cells	  utilize	  to	  their	  own	  advantage	  in	  later	  stages	  
of	  malignancy	   (28,	   29).	  Most	   human	   tumors	   overproduce	   TGF-­‐β	   whose	   autocrine	  
and	   paracrine	   actions	   promote	   tumor	   epithelial	   cell	   invasiveness	   and	   metastasis,	  
functioning	   as	   a	   differentiation	   switch	   required	   for	   transient	   but	   reversible	  
invasiveness	  of	  carcinoma	  cells	  through	  epithelial-­‐to-­‐mesenchymal	  transition	  (EMT)	  
mechanisms	  (30).	  In	  addition	  to	  eliciting	  mitogenic	  signals	  towards	  carcinoma	  cells,	  
TGF-­‐β	   also	   affects	   cancer-­‐associated	   fibroblast-­‐induction	   of	   tumor	   matrix	  
remodeling	   and	   regulates	   angiogenesis	   by	   acting	   on	   endothelial	   cells	   (ECs)	   and	  
pericytes	   (Figure	   2).	   Apart	   from	   the	   preexisting	   classical	   stromal	   components,	  
tumors	  are	  also	   infiltrated	  by	  a	  myriad	  of	  cell	  types:	   leukocytes,	  macrophages,	  and	  
bone	  marrow-­‐derived	  endothelial,	  mesenchymal,	   and	  myeloid	  precursor	   cells	   (31).	  
Finally,	  TGF-­‐β	  suppresses	  proliferation	  and	  differentiation	  of	  lymphocytes	  including	  T	  
cells	   and	  natural	   killer	   cells,	   thus	  preventing	   immune	   surveillance	   control	  over	   the	  
developing	  tumor.	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Figure	  2.	  TGF-­‐β	  in	  the	  tumor	  microenvironment.	  (A)	  Illustration	  of	  TGF-­‐β	  affecting	  multiple	  cell	  types	  
in	   the	   tumor	  microenvironment.	   TGF-­‐β	   promotes	   increased	  epithelial	   invasiveness	   triggering,	   in	   an	  
autocrine	   and	   paracrine	   fashion,	   a	   cell	   plasticity	   program	   called	   EMT.	   Tumor	   cells	   that	   have	  
undergone	   EMT	   can	   therefore	   intravasate	   into	   the	   bloodstream	   and	   migrate	   to	   distant	   sites	   of	  
metastasis.	   TGF-­‐β	   also	   affects	   tumor	   extracellular	   matrix	   (ECM)	   remodeling	   by	   cancer-­‐associated	  
fibroblasts	   (CAFs)	   and	   regulates	   angiogenesis	   by	   acting	   on	   endothelial	   and	   mural	   cells.	   Tumor	  
infiltration	   by	   leukocytes,	  macrophages,	   and	   bone	  marrow-­‐derived	   endothelial,	  mesenchymal,	   and	  
myeloid	   precursor	   cells	   is	   also	   mediated	   by	   TGF-­‐β.	   TGF-­‐β,	   as	   an	   immune	   suppressor,	   prevents	  
immune	  surveillance	  control	  over	  the	  developing	  tumor	  by	  inhibiting	  proliferation	  and	  differentiation	  
of	  lymphocytes	  including	  T	  cells	  and	  natural	  killer	  cells.	  (B)	  TGF-­‐β	  abundant	  expression	  in	  a	  Rip1-­‐Tag2	  
tumor	  (red)	  by	  the	  tumor	  cells	  (blue),	  especially	  in	  the	  vicinity	  of	  vessels	  (green).	  
	  	  
	  
In	  a	  few	  words,	  TGF-­‐β	  signaling	   is	   intimately	   implicated	  in	  tumor	  development	  and	  
contributes	  to	  all	  hallmarks	  of	  cancer	  described	  by	  Hanahan	  &	  Weinberg	  (32-­‐34).	  It	  
is,	   thus,	   of	   vital	   importance	   to	   carefully	   analyze	   the	   role	   of	   the	   TGF-­‐β	   family	  
members	  in	  the	  tumor	  microenvironment	  and	  how	  its	  signaling	  circuits	  arising	  from	  
tumor	  and	  stromal	  interactions	  can	  be	  efficiently	  modulated	  in	  cancer	  therapy.	  	  
	  
1.3.	  Tumor	  angiogenesis:	  seeking	  alternative	  pathway	  targets	  
It	  is	  well	  established	  that	  in	  order	  for	  a	  tumor	  to	  grow	  beyond	  a	  certain	  size,	  it	  requires	  
the	  recruitment	  of	  its	  own	  blood	  supply	  for	  provision	  of	  oxygen	  and	  nutrients	  (4).	  The	  
conceptual	   idea	   of	   the	   angiogenic	   phenomenon	   as	   a	   target	   in	   cancer	   therapy,	  
originally	  coined	  by	  Philippe	  Shubi	  (35,	  36)	  and	  further	  developed	  by	  Folkman	  (37),	  has	  
been	   extensively	   explored	   as	   an	   additional	   anticancer	   strategy	   in	   the	   last	   decades.	  
Since	  antiangiogenic	  drugs	  aim	  at	  the	  non-­‐malignant	  and	  supposedly	  genetically	  stable	  
tumor	  endothelial	  cells	   (ECs),	   it	  was	  expected	  these	  would	  be	   inherently	   resilient	   to	  
resistance	  acquisition	  (38,	  39).	  
Unfortunately,	   clinical	   benefit	   arising	   from	   conventional	   antiangiogenic	   therapies,	  
aimed	  at	  VEGF,	  conveyed	  a	  modest	  therapeutic	  benefit	  measured	  in	  months	  (15-­‐17).	  
Some	  apprehension	  was	  raised	  by	  recent	  preclinical	  studies	  providing	  evidence	  for	  the	  
development	   of	   resistance	   and	   attainment	   of	   a	   more	   aggressive	   and	   invasive	  
phenotype	  in	  tumors	  that	  have	  been	  treated	  with	  anti-­‐VEGF	  strategies	  (19-­‐21).	  
More	   recently	   and	   as	   a	   result	   of	   the	   inability	   to	   improve	   overall	   survival	   in	   breast	  
cancer	   patients	   with	   metastatic	   disease,	   the	   United	   States	   Food	   and	   Drug	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Administration	  (FDA)	  recently	  revoked	  the	  approval	  of	  the	  VEGF	  neutralizing	  antibody,	  
bevacizumab	  for	  that	  indication	  (40).	  	  
The	  emergence	  of	  resistance	  mechanisms	  towards	  VEGF-­‐targeting	  therapies	  has	  been	  
under	   heated	   debate.	   While	   still	   in	   their	   early	   stages,	   preclinical	   studies	   strongly	  
suggest	   caution	  on	   the	   indiscriminate	  use	  of	   antiangiogenic	   agents,	   as	   tumors	  have	  
been	  described	  to	  become	  refractory	  to	  these	  drugs	  after	  prolonged	  exposure	  (14,	  19-­‐
21,	  41).	  
In	  short,	  the	  angiogenesis	  field	  claims	  for	  novel	  antiangiogenic	  targets	  and	  combined	  
targeted	  strategies	  aiming	  at	  various	  tumor	  cellular	  compartments	  and	  at	  alternative	  
signaling	  pathways	  and	  mechanisms	  on	  how	  these	  signaling	  networks	   impinge	  upon	  
the	  angiogenic	  switch.	  
The	   TGF-­‐β	   signaling	   circuitry	   and	   dynamics	   may	   hold	   central	   roles	   in	   tumor	  
angiogenesis,	   as	   suggested	   by	   developmental	   studies	   genetically	   targeting	   its	  
endothelial	   specific	   receptors	   ALK1	   and	   endoglin.	   Based	   on	   such	   studies,	   we	   have	  
investigated	   the	   potential	   of	   targeting	   ALK1	   and	   endoglin	   in	   tumor	   angiogenesis.	  
Clinical	  studies	  using	  inhibitors	  for	  these	  receptors	  are	  already	  in	  place	  and	  show	  great	  
promise	  in	  directly	  interfering	  with	  the	  formation	  of	  new	  tumor	  vessels,	  while	  leaving	  
normal	  idle	  vasculature	  undisturbed.	  
	  
1.3.1.	  Involvement	  of	  TGF-­‐β 	  in	  vascular	  syndromes	  
In	  vascular	  biology,	  TGF-­‐β	  has	  traditionally	  been	  seen	  as	  a	  differentiation	  regulator	  for	  
vascular	   smooth	  muscle	   cells	   (VSMCs),	  ultimately	   contributing	   to	  vessel	   stabilization	  
and	  maturation	   by	   inducing	   extracellular	  matrix	   (ECM)	   deposition	   and	   inhibiting	   EC	  
migration	  and	  proliferation	  (42).	  
The	   critical	   relevance	   of	   TGF-­‐β	   signaling	   in	   vascular	   development	   was,	   however,	  
recognized	  by	  identification	  of	  mutations	  in	  the	  endothelial	  TGF-­‐β	  receptor	  genes	  in	  a	  
familial	   vascular	   syndrome.	  Germline	   loss-­‐of-­‐function	  mutations	   in	  Alk1	   or	  endoglin	  
are	   causal	   in	   the	   development	   of	   the	   human	   syndrome	   of	   hereditary	   hemorrhagic	  
telangiectasia	   (HHT)	   (43).	   HHT	   is	   characterized	   by	   cutaneous	   telangiectases	   and	  
gastrointestinal	  (GI)	  hemorrhage	  (34,	  35).	  Major	  arteriovenous	  malformations	  (AVMs)	  
occur	   in	   lung,	   liver,	   or	   brain,	   which	   may	   ultimately	   cause	   severe	   morbidity	   and	  
mortality.	   	   Although	  Alk1	   and	   endoglin	   null	  mice	   die	   at	  midgestation	   as	   a	   result	   of	  
severe	   AVMs	   (36,	   37),	  mice	   lacking	   one	   copy	   of	   the	   gene	   for	   either	  Alk1	   (Alk1	   +/-­‐;	  
HHT2)	  or	  endoglin	   (Eng	  +/-­‐;	  HHT1)	  recapitulate	  with	  age	  the	  HHT	  patient	  phenotype	  
(44,	  45).	  
There	   is	   additional	   strong	   evidence	   gathered	   from	   in	   vivo	   studies	   on	   genetically	  
manipulated	  mouse	  models,	   for	   a	  prominent	   role	  of	   the	  TGF-­‐β	   pathway	   in	   vasculo-­‐	  
and	  angiogenesis	  mechanisms	  (43).	   In	  fact,	  deletion	  of	  TGF-­‐β	   family	   ligands	  (TGF-­‐β1,	  
TGF-­‐β2,	  BMP2,	  BMP4)	  (46-­‐48),	  receptors	  (ALK1,	  ALK2,	  ALK3,	  ALK5,	  Endoglin,	  TGF-­‐βRII,	  
BMPRII,	  TGF-­‐βRIII)	  (49-­‐67),	  signaling	  mediators	  (Smad1,	  2,	  4,	  5,	  6,	  8)	  (68-­‐74),	  and	  even	  
target	  genes	  (Id1,	  Id3,	  Fibronectin1,	  Thrombospondin1)	  (75,	  76)	  results	  most	  often,	  in	  
serious	   implications	  on	  the	  developing	  embryonic	  vasculature	   leading,	  ultimately,	   to	  
lethality	   in	  mice	   (43,	  46-­‐52,	  54-­‐74,	  76-­‐82).	  Furthermore,	  many	  of	   these	  genes	  when	  
mutated	   in	  human	  patients	  generate	  a	   series	  of	  vascular	   syndromes	  or	  pathological	  
conditions	  other	  than	  HHT,	  such	  as	  aortic	  aneurism,	  pulmonary	  arterial	  hypertension	  
(PAH),	   Loeys-­‐Dietz	   syndrom,	   fibrodysplasia	   ossificans	   progressiva	   (FOP),	   Marfan	  
syndrome	  type	  2	  (MFS2)	  and	  Ehlers-­‐Danlos	  syndrome.	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Increasing	  attention	  has	  been	  focused	  on	  the	  endothelial-­‐cell	  specific	  TGF-­‐β	  receptors	  
ALK1	   and	   endoglin.	   Not	   only	   do	   ALK1	   and	   endoglin	   already	   have	   documented	  
involvement	   in	   the	   human	   syndrome	   HHT	   but	   more	   importantly,	   they	   hold	  
therapeutic	   promise	   in	   pathological	   conditions,	   such	   as	   cancer,	   where	   their	  
upregulated	  expression	   in	   the	  vascular	   component	   indicates	  a	   critical	   role	   in	   cancer	  
development.	  	  
	  
1.3.2. TGF-­‐β 	  signaling	  in	  endothelial	  cells:	  ALK1/ALK5	  interconnecting	  crosstalk	  
Following	   synthesis,	   secretion	   and	   activation,	   the	   mature	   TGF-­‐β	   dimeric	   ligand	   is	  
released	  from	  the	  ECM	  to	  trigger	  specific	  serine/threonine	  type	  I	  and	  type	  II	  kinase	  
receptor	   heterotetrameric	   complexes	   (83).	   In	   ECs,	   TGF-­‐β	   signaling	   has	   been	  
described	  to	  occur	  via	  the	  ubiquitously	  and	  globally	  expressed	  type	  I	  receptor,	  ALK5	  
or	   alternatively	   through	   the	   predominantly	   endothelial	   type	   I	   receptor,	   ALK1.	   The	  
prevailing	   recruited	   type	   I	   receptor	   dictates	   the	   activation	   of	   a	   particular	   Smad	  
transducing	   cascade.	   ALK1	   activation	   causes	   phosphorylation	   of	   Smad1,	   5	   and	   8,	  
whereas	  ALK5	  leads	  to	  Smad	  2	  and	  3	  signaling	  activation	  (37).	  The	  selected	  activated	  
Smad	  subset	   independently	   forms	  a	  heteromeric	  complex	  with	  a	  related	  molecule,	  
Smad4,	  which	  translocates	  the	  complexes	  into	  the	  nucleus	  to	  launch	  transcription	  of	  
specific	   target	   genes	   (38,	   39),	   that	   are	   eventually	   involved	   in	   distinct	   angiogenic	  
responses	  (Figure	  3).	  
	  
Figure	  3.	  Schematic	   illustration	  of	  signaling	  events,	   triggered	  by	  the	  TGF-­‐β	  family,	   in	  endothelial	  cells.	  
TGF-­‐β	   activates	   signaling	   via	   the	   EC-­‐restricted	   ALK1,	   and	   the	   ubiquitously	   expressed	   ALK5,	   type	   I	  
receptors,	  whereas	  BMP9	  only	  binds	  ALK1.	  The	  affinity	  of	  BMP9	  for	  ALK1	  is	  ten-­‐fold	  higher	  than	  that	  of	  
TGF-­‐β,	  making	  it	   likely	  that	  ALK1	  predominantly	  interacts	  with	  BMP9	  when	  both	  ligands	  are	  available.	  
Endoglin	  represents	  a	  coreceptor	  that	  modulates	  signaling	  through	  ALK1.	  
	  
	  
TGF-­‐β	   ligands	   also	   interact	   with	   coreceptors	   or	   type	   III	   receptors,	   represented	   by	  
betaglycan	  (TGF-­‐βRIII)	  and	  the	  predominatly	  endothelial	  endoglin.	  However,	  because	  
these	  type	  III	  receptors	  lack	  the	  kinase	  domain,	  they	  essentially	  hold	  a	  mediation	  role	  
in	  ligand	  binding	  and	  signaling	  activation,	  adding	  yet	  another	  level	  of	  regulation	  to	  the	  
TGF-­‐β	  complex	  signaling	  web.	  
Far	  from	  consensual,	  the	  TGF-­‐β	  contribution	  to	  vascular	  biology	  knowledge	  has	  been	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constantly	  under	  debate	  due	  to	  numerous	  paradoxical	  reports	  (84-­‐86)	  
A	  crucial	  role	  in	  angiogenesis	  for	  ALK1,	  was	  first	  described	  in	  a	  study	  reporting	  ALK1	  as	  
pivotal	   for	   smooth	  muscle	   cell	   (SMC)	   recruitment,	   implying	  a	   vital	   role	   for	   the	  TGF-­‐
β/ALK1	  signaling	  axis	   in	  the	  maturation	  or	  resolution	  phase	  of	  angiogenesis	  (49,	  84).	  
On	   the	   other	   hand,	   signaling	   derived	   from	   ALK5	  was	  more	   pronounced	   during	   the	  
activation	   phase	   of	   angiogenesis,	   when	   ECs	   degrade	   the	   perivascular	   basement	  
membrane,	   invade	   and	   migrate	   into	   the	   newly	   available	   space,	   through	   active	  
proliferation	  and	  lumen	  formation.	  The	  balance	  theory	  was	  then	  hypothesized	  for	  the	  
first	  time,	  speculating	  that	  different	  levels	  of	  TGF-­‐β	  ligand	  availability	  would	  determine	  
the	  sequential	  angiogenic	  fate	  and	  control	  the	  properties	  of	  the	  endothelium	  during	  
angiogenesis	   (49).	   In	   parallel	   studies	   Urness	   et	   al.	   (2000)	   presented	   evidence	   for	  
development	  of	  shunts	  between	  arteries	  and	  veins	  and	  severe	  AVMs,	  due	  to	  fusion	  of	  
major	  arteries	  and	  veins	  in	  mice	  lacking	  ALK1	  (50).	  
The	  balance-­‐working	  model	  was	  quickly	  challenged	  when	  Goumans	  and	  colleagues	  
proposed	  that	  TGF-­‐β	  engages	  in	  the	  activation	  of	  ALK1	  signaling	  via	  Smad1/5,	  which	  
concomitantly	   inhibits	  ALK5	  signaling	  through	  Smad2/3	  (85)	  ALK5,	  while	  critical	   for	  
ALK1	  signaling,	  as	  demonstrated	  by	  studies	  on	  ALK5	  deficient	  mouse	  embryonic	  ECs	  
(MEECs),	   commits	   to	   an	   antiangiogenic	   cascade	   of	   events,	   while	   ALK1	   mediates	  
proangiogenic	  activation	  (87)	  These	  studies	  indicated	  that	  TGF-­‐β	  stimulatory	  effects	  
on	  either	  ALK5	  or	  ALK1	  are	  mutually	  exclusive,	   inducing	  differential	   transcriptional	  
activation	  of	  Pai-­‐1	   and	   Id1,	   respectively,	  and	  ultimately	  eliciting	  alternative	   sets	  of	  
physiological	  responses.	  	  
Motivated	  by	  the	  fact	  that	  both	  ALK1	  and	  ALK5	  null	  mice	  render	  an	  embryonic	  lethal	  
phenotype	   due	   to	   extensive	   vascular	   abnormalities	   (49-­‐51).	   ALK1	   dependency	   on	  
ALK5,	   by	   means	   of	   signaling	   or	   by	   mere	   anchoring,	   has	   been	   questioned	   and	  
addressed	  with	  reservation	  by	  multiple	  laboratories.	  
Transcriptional	   profiling	   of	   human	   umbilical	   vein	   ECs	   (HUVECs)	   expressing	  
constitutively	  active	  adenoviral	  constructs	  of	  ALK1	  or	  ALK5	  demonstrated	  substantial	  
differences	  in	  the	  transcriptional	  output	  from	  either	  signaling	  pathway	  (88),	  validating	  
previously	  described	  downstream	  gene	  regulation.	  Interestingly,	  the	  non-­‐overlapping	  
expression	  patterns	  of	  ALK1	  and	  ALK5	   in	  vivo	   (89)	  by	  thorough	  analysis	  of	  a	  knockin	  
mouse	  line	  carrying	  a	  lacZ	  reporter	  in	  the	  Alk5	  gene	  locus	  (Alk5lacZ),	  also	  lends	  support	  
to	   divergent	   roles	   in	   vascular	   development	   for	   each	   of	   the	   two	   type	   I	   receptors	  
expressed	  by	  ECs.	  	  
ALK5	  suppression,	  by	  genetic	  silencing	  or	  small	  molecule	  inhibition,	  was	  shown	  not	  to	  
interfere	  with	  BMP9/ALK1-­‐induced	  phosphorylation	  of	  Smad1/5/8	  in	  bovine	  aortic	  ECs	  
(BAECs)	  (90).	  Instead,	  silencing	  of	  Alk1	  or	  any	  of	  its	  downstream	  molecular	  effectors,	  
by	   means	   of	   siRNA	   transfection,	   rather	   induces	   a	   potent	   upregulation	   of	   ALK5	  
signaling.	  In	  agreement	  with	  the	  ALK5-­‐independent	  action	  of	  ALK1	  is	  the	  notion	  that	  
the	   former	   is	   present	   in	   ECs	   in	   vivo	   either	   at	   low	   levels,	   or	   only	   expressed	   by	   the	  
neighboring	   VSMCs,	   suggesting	   that	   ALK5	   may	   only	   participate	   in	   ALK1-­‐dependent	  
angiogenesis	  in	  a	  paracrine	  fashion	  (62,	  90).	  Congruent	  with	  these	  results,	  EC-­‐specific	  
ablation	   of	   Alk5	   does	   not	   inflict	   vascular	   abnormalities	   in	   mice	   or	   zebrafish	   (62).	  
However,	   embryos	   from	   knockin	   mice	   carrying	   a	   mutation	   on	   L45	   loop	   in	   ALK5	  
rescued	   to	   some	   extent	   the	   earliest	   vascular	   defects	   observed	   in	   ALK5	   complete	  
knockouts	   (91).	   It	   is	   feasible	   that	   this	   mutation	   while	   interfering	   with	   ALK5	   kinase	  
ability	  to	  phosphorylate	  Smad2	  it	   inherently	  preserves	  ALK5	  competence	  to	  mediate	  
non-­‐Smad	  signaling	  and	  lateral	  signaling	  to	  ALK1.	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In	  agreement	  with	  the	  latter	  findings,	  in	  pathological	  conditions,	  ALK1	  signal	  inhibition	  
proved	  to	   interfere,	  not	  only	  with	   its	  own	  target	  genes	  but	  ALK5	  signal	  transduction	  
also	   suffered	   suppressive	   modulation,	   in	   a	   model	   of	   pancreatic	   neuroendocrine	  
tumors	  (PNETs)	  (92).	  
More	  recently,	  it	  has	  been	  demonstrated	  that	  selective	  deletion	  of	  Alk5	  in	  ECs,	  using	  
an	   Alk1GFPCre	   mouse	   line	   results	   in	   embryonic	   lethality	   due	   to	   brain	   vessel	  
pathological	   morphology	   and	   intracerebral	   hemorrhage	   (93).	   Independent	  
observations	   of	   EC-­‐specific	   deletion	   of	   Smad2/3	   using	   Tie2-­‐Cre	   transgenic	   mice	  
revealed	  critical	  hemorrhaging	  and	  embryonic	   lethality	  around	  E12.5.	   In	  this	  study,	  
vascular	  maturation	  was	  incomplete	  owing	  to	  inadequate	  assembly	  of	  mural	  cells	  in	  
the	   vasculature,	   most	   likely	   because	   of	   impaired	   expression	   of	   PDGF-­‐B	   by	   the	  
Smad2/3	  ablated	  endothelium	  (94).	  
Collectively,	   these	   reports	   substantiate	   that	   ALK5	   signaling	   is	   indeed	   relevant	   for	  
endothelial	   homeostasis	   either	   as	   a	   signaling	   anchor	   to	   ALK1	   or	   by	   actively	  
participating	   in	   the	   vasculogenic	   process.	   Further	   studies	   aiming	   at	   dichotomizing	  
ALK1	   versus	   ALK5	   signaling	   in	   endothelial	   and	   in	   perivascular	   cells	   during	  
development	   and	   in	   the	   tumor	  microenvironment	   are	   thus	   required	   to	   clarify	   and	  
conciliate	   previous	   paradoxical	   observations	   and	   infer	   about	   the	   benefit	   or	   risk	   of	  
clinically	   targeting	   such	  pathways	  without	  proper	   amendments.	   It	   is	   plausible	   that	  
the	   relative	   stoichiometry	   of	   ALK1	   and	   ALK5	   signaling	   may	   be	   crucial	   for	   proper	  
regulation	  of	  gene	  expression	  (95).	  
	  
1.3.3.	  Bone	  morphogenetic	  proteins	  (BMPs)	  
The	  BMPs,	   a	   subcategory	   of	   the	   TGF-­‐β	   superfamily,	  were	   first	   identified	   in	   extracts	  
from	  bone	  matrix	  and	  characterized	  by	  their	  ability	  to	  induce	  ectopic	  bone	  formation	  
when	   implanted	  subcutaneously	   in	  rats	   (96).	   It	   soon	  became	  clear	   that	  BMPs	  play	  a	  
key	  role	  in	  vertebrate	  organogenesis	  as	  well	  as	  in	  embryonic	  vascularization	  (97-­‐99).	  
The	  BMP	  family,	  including	  the	  growth	  and	  differentiation	  factors	  (GDFs),	  comprises	  a	  
group	  of	  20	  ligands	  that	  activate	  a	  classical	  BMP	  pathway	  in	  vertebrates	  (100,	  101).	  In	  
the	   canonical	   BMP	   signaling	   pathway,	   three	   type	   II	   receptors	   (BMPRII,	   ActRIIa	   and	  
ActRII2b)	  and	  four	  type	  I	  receptors	  (ALK1,	  ALK2,	  ALK3	  and	  ALK6)	  can	  be	  activated	  (59,	  
60).	   In	  addition	   to	  primarily	   triggering	  Smad1,	  5	  and	  8,	  BMP	  cues	  may	  also	  activate	  
Smad2	  (61)	  and	  Smad-­‐independent	  signaling	  (102).	  
Making	  an	  analogy	  with	  embryonic	  development	  where	  proper	  ontogenic	  patterning	  
requires	  the	  concerted	  action	  of	  extracellular	  modulators,	  receptors,	  coreceptors	  and	  
cytosolic	   proteins	   orchestrating	   the	   specificity	   and	   accuracy	   of	   signals	   on	  
spatiotemporal	   control,	   it	   is	   predictable	   that	   similar	   mechanisms	   may	   also	   affect	  
homeostasis	  (101,	  102)	  and	  angiogenesis,	  in	  particular	  (99).	  Indeed,	  BMP	  expression	  is	  
also	  detected	  in	  adulthood,	  for	  which	  reason,	  one	  can	  antecipate	  that	  its	  deregulation	  
may	  be	  intimately	  connected	  to	  pathological	  conditions.	  
	  
1.3.4. BMP9	  signaling	  in	  endothelial	  cells	  
BMP9	   has	   been	   implicated	   in	   hematopoiesis,	   hepato-­‐,	   osteo-­‐,	   chondro-­‐	   and	  
adipogenesis	   (102-­‐106).	   It	   has	   also	   been	   described	   as	   a	   regulator	   of	   glucose	  
metabolism	   (107)	   and	   as	   a	   differentiation	   factor	   for	   cholinergic	   neurons	   in	   the	  CNS	  
(108).	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More	   recently,	   BMP9	   was	   pinpointed	   as	   the	   physiologically	   functional	   high	   affinity	  
ligand	   for	   the	   predominantly	   endothelial	   receptor,	   ALK1,	   highlighting	   BMP9	   as	   a	  
critical	  modulator	  of	  angiogenesis	  (109-­‐111).	  
BMP9	  was	  originally	   cloned	   from	  a	   rodent	   cDNA	   library	  obtained	   from	  mouse	   liver,	  
where	   it	   was	   shown	   to	   be	   highly	   expressed	   (112).	   Accordingly,	   the	   liver	   was	  
characterized	   as	   the	   major	   source	   of	   human	   and	   mouse	   BMP9,	   expressed	   by	  
hepatocytes	  and	  intrahepatic	  biliary	  epithelial	  cells,	  while	  it	  is	  present	  in	  the	  brain	  and	  
lung	  at	  much	   lower	   levels	   (113).	   In	   line	  with	  these	  observations,	   the	  Human	  Protein	  
Atlas	  profile	   for	  BMP9	   in	  normal	   tissues	   indicates	   that	   it	   is	  highly	  expressed	   in	   liver,	  
pancreas,	   placenta,	   lung,	   epididimus,	   GI	   tract,	   gall	   bladder	   and	   thyroid,	   but	   also	   in	  
hematopoietic	  cells	  (www.proteinatlas.org).	  
Interestingly,	   it	   is	   now	   clearly	   described	   that	   pulmonary	   and	   cerebral	   AVMs	   occur	  
more	   often	   in	   HHT1	   (caused	   by	   endoglin	  mutation),	   while	   hepatic	   AVMs	   are	  more	  
frequent	  in	  HHT2	  (caused	  by	  ALK1	  mutation)	  (114).	  In	  fact,	  in	  HHT2,	  the	  frequency	  of	  
hepatic	  AVMs	  is	  between	  38-­‐41%,	  while	  in	  HHT1	  it	  only	  ranges	  between	  2.5-­‐8%	  (115).	  
The	  specific	  expression	  of	  the	  ALK1	  ligand,	  BMP9,	  predominantly	  in	  the	  liver	  reflects	  a	  
seemingly	  tissue-­‐specific	  manifestation	  in	  HHT2	  (110).	  	  
The	  modus	  operandus	  of	  BMP	  ligand	  interaction	  with	  their	  receptors	  differs	  from	  that	  
of	  TGF-­‐β:	  while	  TGF-­‐β	  exhibits	  higher	  affinity	  for	  type	  II	  receptors	  and	  does	  not	  stably	  
interact	  with	  type	  I	  receptors	  alone,	  BMPs	  bind	  independently	  to	  both	  type	  I	  and	  type	  
II	   receptors	   (116,	   117).	   The	   BMP	   ligands	   also	   display	   affinity	   to	   the	   coreceptors	  
endoglin	  and	  betaglycan	  (101).	  In	  fact,	  BMP9	  can	  also	  directly	  bind	  endoglin	  (111).	  
BMP9	  is	  synthesized	  as	  a	  precursor	  protein,	  which	  is	  then	  cleaved	  by	  furin,	  a	  serine-­‐	  
endoprotease,	   forming	   a	   short	   dimeric	   mature	   form	   to	   which	   the	   prodomain	   can	  
remain	  non-­‐covalently	   associated	   (113).	  Until	   recently	   neither	  BMP9,	   nor	   its	   closely	  
related	   family	  member,	   BMP10	  were	   found	   to	   be	   negatively	   regulated	   by	   common	  
BMP	   pathway	   antagonists	   (109,	   118).	   However,	   recent	   studies	   showed	   that	   ALK1	  
activation	  by	  BMP9	  induces	  expression	  of	  matrix	  Gla	  protein	  and	  crossveinless	  2	  (CV2),	  
both	  known	  as	  antagonists	  of	  BMP4-­‐induced	  angiogenesis	  (119-­‐121).	  CV2,	  a	  member	  
of	  the	  Chordin	  family,	  preferentially	  binds	  and	  inhibits	  BMP9	  thereby	  providing	  strong	  
feedback	   inhibition	   on	   ALK1	   (119),	   which	   suggests	   a	   critical	   mutual	   regulation	   by	  
BMP9	  and	  CV2	  in	  the	  vasculature.	  
Analogous	  to	  TGF-­‐β	  signaling	  mediated	  by	  ALK1,	  BMP9	  has	  also	  been	  reported	  to	  have	  
incongruent	   effects	   on	   ECs.	   For	   example,	   BMP9	   exhibits	   antiangiogenic	   effects	  
counteracting	   fibroblast	   growth	   factor	   (FGF)-­‐induced	   angiogenesis	   in	   ex	   vivo	  
metatarsal	  models	  (110,	  111)	  and	  acts	  as	  a	  circulating	  vascular	  quiescent	  factor	  (109).	  
Nevertheless,	   multiple	   types	   of	   ECs	   activate	   their	   proliferative	   status	   in	   vitro	   in	  
response	   to	   BMP9,	   which	   proangiogenic	   properties	   also	   activate	   matrigel	   plug	  
vascularization	  and	  tumor	  angiogenesis	  in	  a	  pancreatic	  cancer	  xenograft	  model	  (122).	  
In	  order	  to	  unmistakably	  clarify	  the	  effects	  on	  the	  endothelium	  by	  BMP9	  stimulation	  
and	   its	   specific	   downstream	  mediators,	   an	   extensive	   analysis	   of	   BMP9	  downstream	  
activation	  in	  comparison	  to	  other	  ligands	  on	  ECs	  is	  mandatory	  for	  the	  field.	  According	  
to	   the	   present	   knowledge,	   BMP-­‐induced	   responses	   have	   as	   common	   denominators	  
the	   Smad1/5/8	   pathway	   and	   Id1,	   2	   and	   3	   as	   target	   genes,	   suggesting	   that	   other	  
differentially	  responsive	  genes	  may	  exist,	  more	  specifically	  induced	  by	  each	  BMP.	  In	  a	  
recent	  study	  such	  efforts	  were	  initiated	  where	  EC-­‐specific	  Smad1/5	  target	  genes	  were	  
characterized	  and	  upregulation	  of	  Notch	  signaling-­‐related	  genes	  were	  identified	  upon	  
BMP9	   stimulation	   (123).	   Moreover,	   a	   novel	   embryonic	   endothelium-­‐enriched	   gene	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activated	   by	   BMP9	   and	   BMP10	   through	   the	   ALK1	   receptor,	   Tmem100,	   has	   been	  
described	  (124).	   Interestingly,	  Tmem100	  null	  mice	  exhibit	  embryonic	   lethality	  due	  to	  
impaired	   differentiation	   of	   arterial	   endothelium	   and	   defects	   of	   vascular	  
morphogenesis,	  phenocopying	  the	  Alk1	  complete	  knockout	  (49,	  50,	  124).	  
Despite	   the	   paucity	   of	   detailed	   studies	   on	   the	   involvement	   of	   BMP9	   in	   cancer	  
pathology,	   the	   Human	   Protein	   Atlas	   profile	   in	   cancer	   disease	   indicates	   that	   BMP9	  
expression	  is	  increased	  in	  colorectal	  cancer,	  head	  and	  neck	  squamous	  cell	  carcinoma,	  
pancreatic	  and	  liver	  cancers	  (www.proteinatalas.com).	  Interestingly,	  BMP9	  is	  primarily	  
expressed	   in	   the	   islets	   of	   Langerhans	   in	   the	   pancreas,	   by	   the	   tumor	   cellular	  
component,	  in	  mouse	  PNETs	  and	  is	  increasingly	  expressed	  in	  the	  malignant	  lesions	  as	  
the	   tumorigenic	  pathway	  progresses	   (92).	   There	   is	   therefore	   strong	  evidence	   for	  an	  
important	  functional	  role	  of	  BMP9/ALK1	  signaling	  in	  cancer	  progression.	  
	  
1.3.5. Other	  proangiogenic	  observations	  in	  the	  TGF-­‐β	  signaling	  pathway	  
Both	  BMP9	  and	  BMP10	  have	  been	  identified	  as	  functional	  activators	  of	  ALK1	   in	  ECs,	  
inducing	  comparable	  cellular	  effects.	   In	  agreement	  with	  a	  65%	  amino	  acid	  sequence	  
homology	   between	   both	   ligands,	   BMP10,	   much	   like	   BMP9,	   exhibits	   angiostatic	  
properties	   on	   human	   dermal	   microvascular	   ECs	   (HMVECs)	   (110).	   BMP10,	   however,	  
binds	   to	   ALK1	   with	   lower	   affinity	   than	   BMP9	   (110)	   and	   is	   mainly	   expressed	   in	   the	  
murine	   embryonic	   and	   postnatal	   heart.	   The	   lethally	   impaired	   cardiac	   growth	   and	  
physiology	   in	  the	  BMP10	  knockout	  mouse,	  coupled	  to	  normal	  vascular	  development	  
of	   embryo	   and	   yolk	   sac	   propose	   a	   critical	   role	   for	   BMP10	   in	   cardiogenesis	   (125).	  
Interestingly,	  it	  has	  also	  been	  demonstrated	  that	  BMP10	  can	  additionally	  bind	  to	  ALK3	  
(126).	  Of	  note,	  ALK3	  targeted	  deletion	  in	  neural	  crest	  cells	  generates	  embryonic	  heart	  
failure	  (127).	  Comprehensively,	  these	  observations	  suggest	  the	  cardiac-­‐specific	  nature	  
of	  BMP10	  signaling	  most	  likely	  through	  ALK3,	  rather	  than	  ALK1.	  
However,	  the	  direct	  effect	  of	  BMP10	  on	  the	  vasculature	  should	  not	  be	  overlooked,	  as	  
it	   has	   the	   potential	   to	   cooperate	   or	   even	   compensate	   for	   BMP9	   signaling	   through	  
ALK1.	  In	  fact,	  very	  recently	  Ricard	  et	  al.	  (2012)	  revealed	  that	  BMP9	  knockout	  (KO)	  mice	  
do	  not	  exhibit	  defective	  vascularization	  in	  the	  retina	  (128).	  However,	  injection	  of	  the	  
extracellular	  domain	  of	  ALK1	  or	  a	  neutralizing	  anti-­‐BMP10	  antibody	   impaired	  retinal	  
vascularization	   in	   BMP9-­‐KO	   neonates,	   reducing	   retinal	   vascular	   expansion	   and	  
exacerbating	   vascular	   density	   (128).	   These	   data	   thus	   sustain	   a	   cooperative	   or	  
compensatory	   role	   for	   BMP9	   and	   BMP10	   in	   postnatal	   vascular	   remodeling	   of	   the	  
retina.	  It	  remains	  to	  be	  determined	  if	  this	  cooperative	  role	  occurs	  also	  in	  the	  context	  
of	  cancer.	  Of	  note	  is	  the	  peak	  of	  expression	  of	  BMP10	  only	  during	  the	  angiogenic	  stage	  
of	   tumorigenesis	   in	   the	  Rip1-­‐Tag2	  model	   (50),	  which	  may	  suggest	  a	   role	  during	  that	  
phase	  of	   tumor	  development	   in	  PNETs,	  especially	   in	   the	  absence	  of	  BMP9,	  which	   is	  
more	  abundantly	  expressed.	  
	  
1.3.6. ALK1	  interplay	  with	  other	  type	  I	  receptors	  
The	   complexity	   of	   TGF-­‐β	   and	   BMP9	   signaling	   circuitry	   in	   ECs	   is	   far	   from	   being	  
completely	  represented	  by	  the	  usual	  simplistic	   two-­‐route	  mechanism	  between	  ALK1	  
and	   ALK5	   as	   illustrated	   in	   Figure	   3.	   As	   mentioned	   earlier,	   ALK1	   shares	   similar	  
properties	   in	   terms	   of	   BMP-­‐dependent	   activation	   of	   Smad1/5/8	   signaling	   with	   the	  
related	  BMP	   type	   I	   receptors	  ALK2,	  ALK3	   and	  ALK6.	   Ligand	   specificity	   has	   not	   been	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carefully	  elucidated,	  and	  many	   ligands,	   including	  BMP2,	  BMP4,	  BMP6,	  BMP7,	  BMP9	  
and	   BMP10,	   exhibit	   a	   multitude	   of	   effects	   on	   ECs,	   ranging	   from	   metabolism,	  
endothelial-­‐to-­‐mesenchymal	   transition	   (EndMT)	   and	   tumor	   angiogenesis	   (129-­‐135).	  
While	   described	   as	   the	   physiological	   ligand	   for	   ALK1,	   BMP9	   has	   also	   documented	  
binding	  ability	  towards	  ALK2	  in	  non-­‐EC,	  such	  as	  myoblasts	  and	  breast	  tumor	  cells	  (111)	  
with	  the	  BMP9/ALK2	  signaling	  axis	  also	  being	  linked	  to	  promotion	  of	  proliferation	  of	  
ovarian	   cancer	   cells	   (136).	   In	   support	   of	   the	   need	   for	   substantial	   analysis	   of	   the	  
signaling	   arising	   from	   these	   receptors	   in	   the	   endothelium,	   vascular	   ECs	   have	   been	  
shown	  to	  transform	  into	  multipotent	  stem-­‐like	  cells	  in	  an	  ALK2-­‐dependent	  fashion	  in	  
lesions	   from	   individuals	   with	   fibrodysplasia	   ossificans	   progressiva	   (FOP)	   (131).	   This	  
disabling	  disorder	  occurs	  as	  a	  result	  of	  gain-­‐of-­‐function	  mutations	  in	  ALK2	  in	  humans	  
or	  mirrored	  in	  mice	  by	  constitutive	  activation	  of	  ALK2	  signaling	  on	  chondrocytes	  and	  
osteoblasts.	   Lineage	   tracing	   of	   heterotopic	   ossification	   in	   mice	   using	   a	   Tie2-­‐Cre	  
construct	  disclosed	  the	  endothelial	  origin	  of	  these	  cell	  types	  (131).	  In	  agreement	  with	  
this	   finding,	   ECs	   conditionally	   deficient	   for	  ALK2	  do	  not	   succeed	   to	  undergo	  EndMT	  
during	  endocardial	  cushion	  formation	  in	  embryogenesis	  (137).	  Of	  note,	  ALK2	  has	  been	  
demonstrated	   to	   upregulate	   ALK1	   in	   ECs	   in	   response	   to	   high-­‐density	   lipoproteins;	  
after	  which	  ALK1	   in	   turn	  promotes	   survival	  by	   inducing	  expression	  of	  VEGF-­‐A	   (129).	  
Glucose	   level	  augmentation	  co-­‐regulates	  ALK1	  and	  ALK2	  expression	   in	  human	  aortic	  
ECs	   (HAECs)	   (130).	   Also,	   BMP/TGF-­‐β	   receptors	   appear	   to	   be	   activated	   and	   function	  
sequentially:	  ALK3,	  ALK2,	  ALK1	  and	  ALK5,	  where	  each	   receptor	  can	  possibly	  entail	  a	  
distinct	  function	  and	  correlate	  to	  a	  specific	  stage	  in	  vascular	  growth	  and	  development	  
(90,	  129,	  130).	  
Since	  it	  is	  not	  completely	  clear	  whether	  ALK2	  is	  exclusively	  expressed	  in	  non-­‐ECs,	  more	  
insight	  should	  be	  gathered	  as	  ALK1	  and	  ALK2	  can	  either	  compensate	   for	  each	  other	  
absence	  or	  be	  simultaneously	  targeted	  due	  to	  interaction	  with	  the	  same	  ligands.	  	  
	  
	  
Figure	  4.	  Possible	  network	  crosstalk	  within	  the	  TGF-­‐β	  family	  affecting	  endothelial	  cells.	  TGF-­‐β	  activates	  
both	  ALK1	  and	  ALK5	  type	  I	  receptors	  expressed	  by	  endothelial	  cells,	  whereas	  BMP9	  only	  binds	  ALK1.	  The	  
affinity	  of	  BMP9	  for	  ALK1	  is	  higher	  than	  that	  of	  TGF-­‐β,	  making	  it	  likely	  that	  ALK1	  will	  predominantly	  bind	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BMP9	   when	   both	   ligands	   are	   available.	   In	   addition,	   BMP10	   also	   has	   the	   ability	   to	   bind	   ALK1	   and	  
compensate	   for	   BMP9	   absence.	   Endoglin	   acts	   as	   a	   coreceptor	   modulating	   signaling	   through	   ALK1.	  
Smad1,	   5	   and	   8	   are	   preferentially	   phosphorylated	   and	   activated	   by	   ALK1,	   while	   Smad2	   and	   3	   are	  
predominantly	  activated	  downstream	  from	  ALK5.	  Subsequently,	  Smads	  are	  translocated	  to	  the	  nucleus	  
where	  they	  regulate	  specific	  gene	  expression.	  ALK2,	  ALK3	  and	  ALK6	  may	  compensate	  or	  crosstalk	  with	  
ALK1	  signaling	  cascade	  while	  ALK4	  can	  compensate	  for	  ALK5	  signaling.	  
	  
	  
Thus,	  the	  interplay	  and/or	  compensatory	  crosstalk	  primarily	  between	  ALK1	  and	  ALK2,	  
but	  also	  with	  ALK3	  and	  ALK6,	  which	  is	  of	  critical	  importance	  in	  a	  therapeutic	  context,	  
promptly	  begs	  for	  more	  detailed	  studies	  (Figure	  4),	  especially	  in	  the	  context	  of	  tumors.	  	  
	  
1.3.7. TGF-­‐β 	  and	  BMP	  signaling	  pathways:	  competitive	  or	  synergistic?	  	  
Closely	  connected	  to	  receptor	   interplay	   is	   the	  role	  specifically	  played	  by	  the	   ligands.	  
Classically,	  BMPs	  and	  TGF-­‐βs	  have	   long	  been	  described	  to	  exert	  parallel	  antagonistic	  
effect	  on	  the	  other	  pathway	  in	  a	  variety	  of	  biological	  contexts	  (138).	  
Moreover,	  in	  physiological	  conditions,	  cells	  in	  the	  body	  are	  exposed	  to	  multiple	  ligands	  
simultaneously,	  which	  may	  trigger	  alternative	  responses	  in	  vivo,	  to	  what	  is	  customarily	  
studied	  in	  vitro	  analyzing	  the	  effects	  of	  each	  ligand	  in	  isolation.	  
In	   an	   attempt	   to	   clarify	   the	   role	   of	   ALK1	   signaling	   in	   EC,	   we	   recently	   described	   an	  
unanticipated	   synergistic	   effect	   of	   TGF-­‐β	   with	   BMP9	   on	   tumor	   angiogenesis.	   We	  
demonstrated	  in	  vitro	  and	  in	  vivo	  in	  various	  systems,	  that	  while	  either	  cytokine	  on	  its	  
own	   exerted	   suppressive	   action	   on	   the	   endothelium,	   when	   in	   combination,	   both	  
ligands	   boosted	   the	   EC	   response	   towards	   other	   proangiogenic	   stimuli	   (92).	   On	   a	  
molecular	   level,	   simultaneous	   ECs	   induction	   with	   TGF-­‐β	   and	   BMP9	   induces	   a	  
synergistic	   response	   on	   ALK5	   signaling	   arm,	   demonstrated	   by	   increased	   Smad2	  
phosphorylation	   and	   its	   downstream	   target	   gene	   expression	   (eg.	   Pai-­‐1	   and	   Pdgf-­‐b)	  
(92).	  
Another	   publication	   demonstrated	   that	   BMP2	   synergistically	   enhances	   TGF-­‐β3-­‐
induced	   initial	   phenotypic	   changes	   associated	   with	   EndMT	   occurring	   during	  
endocardial	  cushion	  formation	  (139).	  In	  fact,	  BMPs	  and	  their	  receptors	  are	  expressed	  
at	  many	   sites	   in	  which	   EMT	   or	   EndMT	   occurs	   during	   developmental	   organogenesis	  
(140-­‐142).	  
TGF-­‐β	  and	  BMP7	  also	  coadjuvantly	  stimulate	  angiogenesis	  in	  the	  chick	  chorioallantoic	  
membrane	  (CAM)	  assay	  (135)	  and	  collaboratively	  activate	  prostate	  cancer	  cells	  (143)	  
and	   osteoblast	   differentiation	   (144).	   In	   contrast,	   BMP7	   counteracts	   TGF-­‐β-­‐induced	  
EndMT	   in	   a	   model	   of	   cardiac	   fibrosis,	   rendering	   the	   ECs	   capable	   to	   preserve	   their	  
endothelial	   identity	   (132).	   These	   observations	   suggest	   context-­‐dependency	   of	   the	  
synergy	  between	  TGF-­‐βs	  and	  BMPs.	  
	  
The	  numerous	  BMP	  ligands	  and	  type	  I	  receptors	  exert	  a	  variety	  of	  effects	  on	  ECs,	  yet	  
the	  fact	  that	  different	  ligands	  utilize	  common	  pathway	  components	  raises	  important	  
questions,	   which	   may	   have	   been	   neglected	   until	   recently:	   how	   cells	   respond	  
specifically	  to	  individual	  ligands	  and	  how	  cells	  integrate	  and	  interpret	  signals	  received	  
from	  multiple	  ligands.	  Concerning	  this	  context,	  worthy	  of	  note	  are	  studies	  suggesting	  
that	  pre-­‐formed	  BMP	  receptor	  complexes	  or	  BMP-­‐induced	  oligomerization	  of	   type	   I	  
and	   type	   II	   receptors,	   predominantly	   activate	   Smad-­‐dependent	   or	   –independent	  
signaling,	   respectively	   (145,	   146).	  Also,	   the	   choice	  of	   type	   II	   receptor	   influences	   the	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signaling	  outcome	  of	  BMP	  stimulation	  as	  downstream	  specific	  binding	  of	  Limk1	  to	  the	  
BMP	  type	  II	  receptor,	  but	  not	  to	  TGF-­‐β	  or	  Activin	  type	  II	  receptors,	  have	  been	  reported	  
(147,	   148).	   More	   recently,	   different	   R-­‐Smad	   complex	   formation	   Smad1/5-­‐Smad2	  
versus	   Smad1/5-­‐Smad3	  were	  described	   (138),	  opening	   the	  possibility	   that	   the	  novel	  
complexes	  may	  be	  the	  source	  of	  antagonistic	  versus	  synergistic	  responses	  in	  different	  
studies.	  
	  
Evidently,	   signaling	   through	   non-­‐Smad	   effectors,	   the	   recruitment	   of	   distinct	   type	   II	  
receptors	  and	  perhaps	  more	   importantly	   the	  variability	  created	  by	  alternative	  Smad	  
complex	   formation	   should	  be	   further	  examined,	   as	   the	  explanations	   for	   the	  diverse	  
effects	  may	  rely	  on	  these	  factors.	  
	  
1.4. TGF-­‐β	  endothelial	  signaling	  pathways	  as	  cancer	  pharmacological	  targets	  
1.4.1. Physiological	  role	  of	  ALK1	  in	  the	  vasculature	  
The	  importance	  of	  this	  receptor	  became	  obvious,	  when	  Alk1	   loss	  of	  function	  studies	  
revealed	   that	   its	   complete	   loss	   causes	   embryonic	   lethality	   at	   midgestation,	   due	   to	  
severe	   vascular	   abnormalities	   including	   vessel	   hyperdilation,	   AVMs	   resulting	   from	  
fusion	   of	   major	   arteries	   and	   veins,	   and	   impaired	   recruitment	   of	   VSMC	   (49)	   (50).	  
Mutations	   in	   the	   Alk1	   gene	   have	   been	   identified	   as	   the	   underlying	   cause	   for	  
development	  of	  HHT,	  a	  rare,	  human	  autosomal	  dominant	  disease	  characterized	  by	  the	  
presence	   of	   recurrent	   epistaxis	   and	   small	   characteristic	   malformations	   of	   the	  
peripheral	  blood	  vessels	  near	  the	  surface	  of	  the	  skin	  or	  GI	  mucosal	  linings	  (149).	  AVMs	  
of	   the	   lung,	   liver,	   and	  CNS	  are	  also	   known	  clinical	   findings.	   Interestingly,	   EC-­‐specific	  
deletion	  of	   the	  Alk1	   gene	   in	   the	  mouse	   results	   in	  neonatal	   lethality	   at	   P5,	  with	   the	  
pups	   exhibiting	   hemorrhaging	   in	   the	   brain,	   lung	   and	   GI	   tract	   (150).	   In	   attempts	   to	  
evaluate	   the	  contribution	  of	  ALK1	   to	  vascular	  homeostasis	   in	  adult	  mice,	  Park	  et	  al.	  
(2009)	  deleted	  Alk1	   in	  2	  months	  old	  R26+	   /CreER	  Acvrl12loxP/loxP	  mice	   (150).	  Tamoxifen-­‐
induced	  Alk1	  deletion	  resulted	  in	  severe	  internal	  hemorrhage	  in	  lung,	  small	  intestine,	  
uterine	  vessels,	  and	  ultimately	  in	  death.	  
Strong	   expression	   of	   ALK1	   has	   been	   reported	   during	   developmental	   and	   neonatal	  
stages,	  while	  it	  is	  suppressed	  during	  adulthood,	  except	  in	  certain	  organs,	  i.e.,	  the	  lungs	  
(62).	  Supportive	  of	  that	  is	  the	  observation	  that	  ALK1	  is	  fundamental	  for	  umbilical	  and	  
placental	  blood	  vessel	  formation	  (151)	  and	  its	  expression	  is	  induced	  in	  feeding	  arteries	  
and	   newly	   formed	   blood	   vessels	   during	   wound	   healing	   in	   adult	   subdermal	   blood	  
vessels	   (150).	   AVMs	   appearing	   only	   in	   subdermal	   blood	   vessels	   where	   a	   wound	   is	  
inflicted	  provide	  in	  vivo	  experimental	  evidence	  that	  genetic	  predisposition	  by	  endoglin	  
or	   Alk1	   mutations	   is	   not	   enough	   for	   development	   of	   de	   novo	   AVMs	   in	   HHT	   (62).	  
Interestingly,	   only	   selected	   vascular	   beds	   in	   HHT	   patients	   develop	   telangiectasis	   or	  
AVM	  lesions,	  while	  other	  areas	  (>99.9%)	  remain	  normal	  (152).	  
Three	  independent	  studies	  demonstrated	  that	  inhibition	  of	  ALK1	  by	  systemic	  injection	  
of	   an	   ALK1	   soluble	   extracellular	   domain	   efficiently	   impaired	   retinal	   neonatal	  
angiogenesis,	   inducing	   retinal	   hypervascularization	   and	   appearance	   of	   AVMs	   in	  
neonatal	   mice	   (128,	   153,	   154).	   Incidentally,	   the	   most	   recent	   studies	   also	   report	   a	  
cooperative	   effect	   of	   ALK1	   and	   Notch	   signaling	   pathways	   (123,	   128,	   154).	   The	  
reported	  synergy	  between	  ALK1	  and	  Notch	  pathways	  generated	  exacerbation	  of	  the	  
hypervascularization	   phenotype,	   inducing	   potentiated	   expression	   of	   Notch	   target	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genes	   in	   the	   stalk	   cells,	   which	   concomitantly	   suppress	   VEGF	   signaling	   to	   the	  
endothelial	   tip-­‐cell	   (154).	   In	   parallel	   studies,	   it	   was	   shown	   that	   endothelial-­‐specific	  
inactivation	  of	  Smad1/5	  in	  mouse	  embryonic	  development	  yields	  impaired	  Dll4/Notch	  
signaling	  and	  augments	  tip-­‐cell	  number	  in	  detriment	  to	  stalk	  cell	  number	  (155).	  These	  
studies	   put	   forward	   a	   regulatory	   crosstalk	   loop	   amongst	   BMP9/ALK1/Smad1/5	   and	  
Notch	  signaling	  coordinating	  tip	  versus	  stalk	  cell	  specification.	  	  
Additionally	  to	  being	  expressed	  by	  blood	  ECs,	  ALK1	  is	  also	  expressed	  by	  lymphatic	  ECs	  
(LECs)	  (153).	  In	  vitro	  stimulation	  of	  LECs	  by	  BMP9	  generates	  downstream	  target	  gene	  
transactivation.	   Furthermore,	   inhibition	   of	   ALK1	   signaling	   by	   means	   of	   an	   ALK1-­‐Fc	  
soluble	  fusion	  protein	  diminishes	  neonatal	  retinal	  lymphangiogenesis,	  while	  the	  use	  of	  
an	   ALK1	   targeting	   monoclonal	   antibody	   also	   impairs	   Lyve-­‐1-­‐positive	  
lymphangiogenesis	   in	  mammary	   fat	   pad–implanted	  MDA-­‐MB-­‐231	   breast	   carcinoma	  
xenografts	   (156).	   Lymphatic	   vessel	   development	   seems	   to	   comprise	   coordinate	   and	  
synergistic	  ALK1	  and	  VEGFR3	  signaling	  regulation	  (153),	  reminescent	  of	  the	  crosstalk	  
between	   ALK1/ALK5,	   ALK1/ALK2	   and	   VEGF-­‐receptor	   signaling	   in	   blood	   vessel	  
angiogenesis	  (92,	  157).	  
	  
1.4.1.1. Clinical	  relevance	  of	  ALK1	  in	  cancer	  
	  
ALK1	  expression	  in	  the	  early	  developing	  mouse	  embryo	  coincides	  with	  sites	  of	  vasculo-­‐	  
and	  angiogenesis	  (158),	  with	  prevailing	  expression	  in	  developing	  arterial	  endothelium,	  
while	  nearly	  absent	  from	  small	  capillaries	  (89).	  During	  early	  mouse	  development	  ALK1	  
is	   strongly	   expressed,	   whilst	   it	   tends	   to	   be	   concealed	   in	   the	   adult	   quiescent	  
vasculature.	  The	  expression	  of	  ALK1	   is	   reversibly	   turned	  on	  during	  neo-­‐angiogenesis	  
events	  in	  wound	  healing	  or	  in	  tumors	  (89).	  
Information	   about	   pattern	   and	   intensity	   of	   ALK1	   expression	   in	   human	   normal	   and	  
cancerous	   tissues	   is	   unfortunately	   still	   scarce.	   The	   public	   Human	   Protein	   Atlas	  
program	  (159)	  has	  characterized	  ALK1	  immunostaining	  of	  both	  normal	  and	  neoplastic	  
tissues.	   In	   this	   study,	   ALK1	   exhibited	   frequent	   strong	   expression	   most	   notably	   in	  
neuronal	  cells	  of	   the	  cerebral	  cortex,	  hippocampus,	  ventricle	  and	  cerebellum,	   in	   the	  
gall	  bladder,	  GI	  tract,	  and	  in	  tubular	  cells	  in	  the	  kidney,	  in	  line	  with	  the	  murine	  ALK1	  
expression	   profile	   (160,	   161).	   The	   same	   organization	   identified	   ALK1	   prevailing	  
expression	   in	   neoplasms	   in	   the	   colorectal	   tract,	   pancreas,	   stomach,	   and	   thyroid,	   as	  
well	  in	  malignant	  lymphomas	  and	  melanomas	  (www.proteinatlas.com).	  A	  preliminary	  
descriptive	   study	   reported	   a	   weak	   but	   widespread	   pattern	   of	   expression	   in	   the	  
vasculature	   of	   normal	   tissues,	   including	   positive	   staining	   in	   lymphatic	   tissues,	   lung,	  
intestine	  and	  pancreas	  (162).	  In	  a	  follow-­‐up	  study	  by	  the	  same	  entity,	  ALK1	  was	  found	  
to	   be	   extensively	   present	   on	   tumor	   blood	   vessels,	   especially	   in	   lymphomas,	   and	  
malignant	  tissues	  of	  the	  prostate,	  skin,	  thyroid,	  kidney,	  ovary,	  lung,	  pancreas	  and	  liver	  
(156)	  Thorough	  studies	  analyzing	  the	  prognostic	  strength	  and	  diagnostic	  significance	  
of	  ALK1	  are	  highly	  warranted.	  
	  
1.4.1.2. Inhibitory	  molecules	  targeting	  ALK1	  
	  
Given	   the	   extensive	   literature	   describing	   paradoxical	   effects	   of	   signaling	   stemming	  
from	  ALK1	  in	  ECs,	  predicting	  the	  net	  outcome	  for	  acute	  inhibition	  of	  ALK1	  in	  cancer	  is	  
an	  intricate	  task.	  Furthermore,	  the	  complex	  ligand-­‐receptor	  binding	  specificity	  and/or	  
redundancy	  within	   the	  TGF-­‐β	   family	  adds	  multiple	  hurdles	   in	  estimating	   therapeutic	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efficacy,	   benefit	   and	   side	   effects	   for	   the	   various	   ALK1	   inhibitors	   currently	   under	  
development.	  	  
Small	  molecules	  comprising	  a	  broad	  inhibitory	  spectrum	  against	  BMP	  type	  I	  receptor	  
kinases,	   including	   ALK1,	   have	   been	   generated.	   Smad-­‐dependent	   and	   -­‐independent	  
signaling,	  induced	  by	  BMPs	  can	  be	  blocked	  by	  compounds	  such	  as	  dorsomorphin	  and	  
its	  analogue	  LDN-­‐193189	   (163,	  164).	  These	  compounds	  can	  be	  useful	  and	  potent	   in	  
inhibiting	  BMP	  type	  I	  receptor	  signaling	  in	  a	  range	  of	  diseases	  and	  familial	  syndromes	  
(165).	   However,	   their	   effect	   on	   BMP-­‐induced	   tumor	   angiogenesis	   remains	   to	   be	  
determined.	  Non-­‐selective	   inhibitors	  also	  raise	  the	  concern	  of	  off-­‐target	  effects,	  and	  
dorsomorphin	  was	  in	  fact	  recently	  reported	  to	  potently	  inhibit	  multiple	  kinases	  (166,	  
167).	   Further	  development	  of	   small	  molecule	  with	   a	  more	   specific	   inhibition	  profile	  
aiming	   primarily	   at	   BMP	   type	   I	   receptors,	   and	   specifically	   towards	   ALK1,	   should	   be	  
considered.	  
Antibodies	  or	  soluble	  extracellular	  receptor	  domain	  traps	  may	  alternatively	  provide	  a	  
tighter	   inhibition	   of	   specific	   ALK1	   activity.	   ALK1	   inhibitors	   are	   currently	   under	  
development	   for	   cancer	   treatment	   as	   antiangiogenic	   drugs.	   Up	   to	   now,	   several	  
biological	  inhibitors	  against	  ALK1	  have	  been	  generated	  for	  in	  vivo	  use.	  Firstly,	  Pfizer	  is	  
currently	   conducting	   phase	   I	   trials	   with	   PF-­‐03446962,	   a	   fully	   human	   monoclonal	  
antibody	   against	   ALK1	   (168).	   Secondly,	   Genentech	   reported	   the	   use	   of	   an	   ALK1-­‐Fc	  
fusion	   protein	   (amino	   acids	   23-­‐119	   of	  mouse	   ALK1),	   on	  mouse	   hematogenous	   and	  
lymphatic	   vessel	   development	   studies	   (153).	   Another	   ALK1-­‐targeting	   agent	   is	  
Dalantercept/ACE-­‐041	   (mouse	   counterpart	   RAP-­‐041,	   amino	   acids	   22-­‐117	   of	   mouse	  
ALK1)	  (169),	  a	  human	  ALK1-­‐Fc	  fusion	  protein,	  currently	  undergoing	  a	  phase	  II	  clinical	  
trials	  coordinated	  by	  Acceleron	  Pharma.	  	  
	  
PF-­‐03446692	  
Preclinical	   tumor	   studies	   using	   PF-­‐03446962	   have	   recently	   been	   reported	   by	   Pfizer	  
(156).	  ALK1	  blockade	  exhibited	  attenuation	  of	  VEGF-­‐induced	  EC	  proliferation	  and	  tube	  
formation	   in	   vitro.	   In	   addition,	   therapeutic	   treatment	   with	   the	   ALK1-­‐neutralizing	  
antibody	   delays	   tumor	   growth	   in	   vivo	   in	   MDA-­‐MB-­‐231	   breast	   carcinoma	   and	  
M24met/R	  melanoma	  mouse	  models	  (156).	  
The	  anti-­‐hALK1	  antibody	   from	  Pfizer	   is	  currently	   in	  phase	   I	   clinical	   trials	   for	  patients	  
with	  advanced	  solid	  tumors	  (168).	  The	  primary	  endpoint	  for	  the	  study	  is	  to	  determine	  
a	  maximum	   tolerated	   dose	   (MTD)	   for	   phase	   II	   trials,	   whereas	   secondary	   outcomes	  
include	   the	   record	   of	   preliminary	   signs	   of	   antitumor	   activity	   and	   tumor	   blood	   flow.	  
Preliminary	  evidence	  from	  the	  trial	  indicates	  that	  the	  anti-­‐hALK1	  antibody	  reduced	  the	  
amount	   of	   ALK1-­‐positive	   circulating	   ECs	   (170),	   which	   were	   found	   to	   be	   present	   in	  
increased	   levels	   in	  advanced	  stage	  cancer	  patients	   (171).	  The	  PF-­‐03446962	  antibody	  
was	  well	   tolerated	  at	  doses	  up	   to	  10	  mg/kg	  and	  did	  not	  present	   significant	  adverse	  
events	   in	   all	   44	   patients	   participating	   in	   the	   phase	   I	   trial.	   The	   most	   common	   side	  
effects	   included	   transient	   thrombocytopenia	   and	   asymptomatic	   elevation	   of	  
pancreatic	   enzymes.	   Hence,	   preliminary	   observations	   evoke	   encouraging	   clinical	  
activity	  where	  three	  partial	  responses	  were	  observed	  in	  patients	  who	  have	  previously	  
received	  fruitless	  VEGF-­‐targeting	  antiangiogenic	  regimens	  (168).	  A	  phase	  II	  clinical	  trial	  
on	  relapsed	  or	  refractory	  urothelial	  cancer	  is	  already	  planned	  (www.clinicaltrials.gov).	  
The	  mechanism	  of	  action	  of	  this	  antibody	  has	  recently	  been	  described	  (172).	  The	  anti-­‐
hALK1	  antibody	  selectively	  recognizes	  human	  ALK1	  and	  interferes	  with	  BMP9-­‐induced	  
signaling	   in	   ECs.	   Moreover,	   the	   anti-­‐hALK1	   antibody	   competitively	   obstructs	   BMP9	  
	  	  18	  
and	   TGF-­‐β	   binding	   to	   ALK1	   receptor	   and	   prevents	   BMP9-­‐dependent	   recruitment	   of	  
endoglin	   into	   the	   angiogenesis-­‐mediating	   signaling	   complex,	   which	   may	   eventually	  
further	  hinder	  the	  BMP9/ALK1	  proangiogenic	  effects.	  	  
	  
Dalantercept/ACE-­‐041/RAP-­‐041	  
The	   effects	   of	   RAP-­‐041	   were	   recently	   analyzed	   in	   the	   Rip1-­‐Tag2	   transgenic	   mouse	  
model	   of	   pancreatic	   neuroendocrine	   tumorigenesis	   (92).	   Rip1-­‐Tag2	   tumors	   readily	  
express	  ALK1	  exclusively	  on	  ECs,	  mirroring	  the	  expression	  profile	  of	  common	  vascular	  
markers	   during	   tumor	   progression.	   Rip1-­‐Tag2	  mice	   treated	   with	   two	   weekly	   doses	  
between	   1-­‐12	  mg/kg	   of	   RAP-­‐041	   results	   in	   a	   dose-­‐dependent	   retardation	   of	   tumor	  
growth	   and	   the	   highest	   dose	   of	   12	   mg/kg	   effectively	   prevents	   further	   tumor	  
expansion.	   Incidentally,	   Alk1	   heterozygous	   mice	   under	   the	   Rip1-­‐Tag2	   context	  
recapitulated	  the	  effects	  obtained	  by	  systemic	  inhibition	  by	  RAP-­‐041.	  Specificity	  of	  the	  
ALK1-­‐targeting	  treatment	  was	  validated	  by	  decreased	  expression	  of	  ALK1	  downstream	  
target	  genes	  in	  tumors	  from	  mice	  treated	  with	  RAP-­‐041.	  Alternative	  studies	  with	  the	  
same	  inhibitor	  demonstrated	  that	  RAP-­‐041	  also	  possesses	  growth-­‐inhibitory	  effect	  in	  
orthotopic	  MCF-­‐7	  breast	  carcinomas	  (157)	  and	  in	  the	  breast	  cancer	  transgenic	  mouse	  
model	  MMTV-­‐PyMT	  (personal	  observation).	  	  
Acceleron	   Pharma	   recently	   concluded	   a	   phase	   I	   trial	   for	   the	   human	   ALK1-­‐Fc	   fusion	  
protein	  Dalantercept/ACE-­‐041	  (169),	  which	  binds	  and	  neutralizes	  BMP9	  and	  BMP10,	  
but	  does	  not	  interact	  with	  any	  of	  the	  TGF-­‐β	  isoforms	  (92,	  157).	  Thirty	  seven	  patients	  
with	  solid	  tumors	  or	  refractory	  multiple	  myeloma	  were	  recruited	  to	  assess	  safety	  and	  
tolerability	   of	   Dalantercept/ACE-­‐041,	   as	   well	   as	   changes	   in	   tumor	   metabolism	  
evaluated	   by	   18F	   deoxyglucose	   positron	   emission	   tomography	   (FDG-­‐PET).	   The	  
Dalantercept/ACE-­‐041	  regimen	  included	  an	  administration	  every	  three	  weeks	  and	  was	  
well	   tolerated	   at	   doses	   up	   to	   1.6	   mg/kg.	   Common	   collateral	   effects	   comprised	  
peripheral	   edema,	   fatigue,	   nausea,	   headache,	   anorexia	   and	   anemia.	   Interestingly,	  
toxicities	  usually	  associated	  with	  VEGF	  inhibition,	  such	  as	  hypertension,	  proteinuria,	  GI	  
tract	  perforation	  and	  hemorrhaging	  were	  not	  observed.	  The	  milder	  side	  effects	  caused	  
by	   ALK1	   inhibition	   are	   probably	   due	   to	   ALK1	   predominant	   expression	   in	   actively	  
cycling	   endothelium	  within	   the	   tumor	  milieu	   and	   preferentially	   localizing	   in	   arterial	  
endothelium,	  whereas	  VEGFRs	  present	  a	  more	  global	  distribution	  (173).	  
In	   this	   clinical	   study,	   one	   patient	   with	   refractory	   head	   and	   neck	   squamous	   cell	  
carcinoma	   (HNSCC)	   exhibited	   a	   partial	   response	   (>30weeks)	   and	   six	   other	   patients	  
exhibited	   stable	   disease.	   Rapid	   reduction	   in	   tumor	   metabolic	   activity	   (>20%)	   was	  
observed	  in	  ten	  patients,	  measured	  by	  FDG-­‐PET	  scanning	  (174).	  Of	  note,	  many	  of	  the	  
patients	   included	   in	   this	   trial	   had	   been	   previously	   inefficiently	   treated	   with	   other	  
therapeutic	  regimens,	  including	  VEGF-­‐neutralizing	  drugs.	  
After	  such	  an	  encouraging	  phase	  I	  clinical	  trial,	  the	  ALK1	  inhibitor	  Dalantercept/ACE-­‐
041	  is	  undergoing	  phase	  II	  clinical	  studies	  with	  expanded	  cohorts	  on	  HNSCC,	  renal	  cell	  
carcinoma	   (RCC)	   and	   recurrent	   or	   persistent	   endometrial	   cancer	   patients	  
(http://clinicaltrials.gov).	  Furthermore,	  BMP9	  has	  been	  shown	  to	  be	  elevated	  and	  may	  
feasibly	  function	  as	  a	  biomarker	  for	  selecting	  patients	  who	  can	  possibly	  benefit	  from	  
Dalantercept/ACE-­‐041.	  In	  fact,	  in	  an	  analysis	  of	  archived	  tumor	  samples	  from	  patients	  
with	   HNSCC,	   79%	   of	   the	   samples	   presented	   with	   moderate	   to	   high	   expression	   of	  
BMP9	   (communication	   from	   Acceleron	   Pharma).	   Apart	   from	   its	   anticancer	  
specification,	  Dalantercept/ACE-­‐041	  is	  also	  being	  developed	  for	  testing	  in	  age-­‐related	  
macular	  degeneration	  (AMD)	  treatment.	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1.4.1.3. Possible	  side	  effects	  from	  ALK1	  inhibition	  
	  
Antiangiogenic	  therapies,	  mainly	  in	  the	  form	  of	  inhibitors	  of	  VEGF	  signaling,	  have	  been	  
in	   routine	   clinical	   use	   for	   several	   years	   for	   various	   malignancies.	   Side	   effects	   from	  
inhibiting	   angiogenesis	   are	   in	   general	   milder	   than	   those	   arising	   from	   conventional	  
chemotherapeutic	   treatment	   and	   include	   most	   frequently	   bleeding,	   hypertension,	  
fatigue,	  and	  nausea.	  Specifically,	  given	  the	  causal	  relationship	  between	  impaired	  ALK1	  
signaling	   and	  HHT-­‐related	   symptoms,	   inhibition	  of	  ALK1	   signaling	   in	   the	   vasculature	  
may	   induce	   de	   novo	   AVMs	   and	   hemorrhaging.	   In	   fact,	   skin	   telangiectasis	   were	  
observed	  in	  a	  patient	  treated	  with	  Dalantercept/ACE-­‐041	  (personal	  communication	  by	  
Acceleron	  Pharma),	  validating	  the	  on-­‐target	  effect	  of	  this	  inhibitory	  agent,	  additionally	  
indicating	  that	  the	  appearance	  of	  telangiectases	  may	  be	  useful	  as	  a	  surrogate	  marker	  
for	   efficacy.	   Loss-­‐of-­‐function	   mutations	   in	   ALK1	   linked	   to	   hereditary	   pulmonary	  
arterial	   hypertension	   (PAH)	   (175)	   highlight	   the	   risk	   for	   pulmonary	   circulation	  
hemodynamic	  perturbations	  with	  ALK1	  inhibitors.	  Importantly,	  complete	  blockade	  of	  
ALK1	   signaling	   triggered	   by	   both	   BMP9	   and	   BMP10	   resulted	   in	   lung	   hemorrhaging	  
(128),	   an	   organ	   that	   should	   thus	   be	   primarily	   supervised.	   Furthermore,	   as	   HHT2	  
symptoms	  seem	  to	  be	  more	  prone	  to	  be	  manifested	  by	  the	  liver	  (110)	  and	  given	  this	  
organ´s	  high	  expression	   levels	  of	  BMP9,	  the	   liver	  should	  also	  be	  carefully	  monitored	  
(113).	   Finally,	   as	   ALK1	   is	   reported	   to	   be	   expressed	   by,	   and	   possibly	   important	   for	  
lymphatic	  ECs,	   cells	  of	   the	  pituitary	  gland,	   chondrocytes	  and	  pancreatic	  ductal	   cells,	  
special	  care	  should	  be	  taken	  to	  record	  adverse	  events	  from	  the	  use	  of	  ALK1	  inhibitors	  
related	  to	  processes	  regulated	  by	  these	  particular	  tissues	  (153,	  176-­‐179).	  
	  	  
1.4.2. Physiological	  role	  of	  endoglin	  in	  the	  vasculature	  
Endoglin,	   an	   auxiliary	   receptor	   for	   TGF-­‐β,	   is	   required	   for	   angiogenesis	   during	  
development	  (180).	  It	  is	  expressed	  primarily	  in	  ECs	  and	  its	  expression	  is	  substantially	  
incremented	  during	  EC	  activation,	   inflammation,	   ischemia,	  and	  tumor	  angiogenesis	  
(181-­‐184).	   The	   mechanisms	   involved	   in	   endoglin	   upregulation	   are	   presumably	  
multifactorial,	   but	   hypoxia	   is	   a	   probable	   inducer	   as	   it	   prevails	   in	   most	  
pathophysiological	  environments	  where	  endoglin	  is	  enhanced	  (185).	  	  
Endoglin	   associates	   with	   type	   II	   receptors	   of	   the	   TGF-­‐β	   family	   in	   the	   presence	   of	  
ligand	  and	  with	  the	  type	  I	  signaling	  receptors,	  ALK1	  and	  ALK5,	  even	  in	  the	  absence	  of	  
exogenous	  ligand	  (186).	  Despite	  possessing	  no	  enzymatic	  activity,	  endoglin	  has	  been	  
reported	  to	  be	  necessary	  to	  modulate	  ligand-­‐receptor	  interaction	  in	  ALK1,	  but	  not	  in	  
ALK5	  signaling	  (111,	  187-­‐189).	  More	  recently,	  ALK5	  was	  shown	  to	  phosphorylate	  the	  
cytoplasmic	   domain	   of	   endoglin	   in	   ECs	   (190).	   Depending	   on	   the	   phosphorilation	  
status	   of	   only	   serine	   646	   or	   both	   646	   and	   649	   serine	   residues,	   response	   to	   TGF-­‐
β/BMP9	   signaling	   results	   in	   loss	   of	   endoglin-­‐mediated	   inhibition	   or	   activation	   of	  
Smad1/5/8	  signaling,	  respectively	  (190).	  Taken	  together,	  these	  results	   indicate	  that	  
endoglin	  phosphorylation	  by	  ALK5	   is	  an	   important	  mechanism	  for	  regulating	  TGF-­‐β	  
and	  BMP	  signaling	  in	  ECs.	  
Even	  though	  endoglin	  has	  an	  undeniably	  well	  documented	  connection	  to	  ALK1	  and	  
its	   signaling	   enhancement	   (189,	   191),	   it	   is	   imperative	   to	  mention	   that	   it	   interacts	  	  
with	   ligands	  other	   than	  TGF-­‐β	  and	  BMP9	  (TGF-­‐β3,	  Activin	  A,	  BMP2	  and	  BMP7)	  but	  
also	  with	   several	  different	   type	   I	  and	   type	   II	   receptors	   involved	   in	  BMP	  and	  TGF-­‐β	  
signaling	   (186).	   A	   crosstalk	   has	   been	   described	   between	   endoglin-­‐mediated	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fibronectin/α5β1	  integrin	  complex	  and	  the	  TGF-­‐β	  pathway.	  	  This	  complex	  alters	  the	  
responses	   of	   ECs	   to	   TGF-­‐β,	   switching	   TGF-­‐β	   from	   promoter	   to	   suppressor	   of	  
migration,	   supporting	   capillary	   stability,	   and	   partially	   mediating	   developmental	  
angiogenesis	  in	  vivo	  (192).	  
Alternatively,	   endoglin	   has	   also	   been	   implicated	   in	   interactions	   with	   cytoplasmic	  
proteins	  such	  as	  Zyxin,	  ZRP-­‐1,	  β-­‐Arrestin	  and	  Tctex2β,	  which	  may	   further	  generate	  
additional	   cellular	   outcomes	   (185).	   The	   unrestrictive	   signaling	   of	   endoglin	  
consequently	  adds	  an	  extra	  degree	  of	   intricacy	  to	  the	  elaborate	  signaling	  networks	  
deriving	   from	   the	   TGF-­‐β	   family	   in	   the	   angiogenesis	   field.	  Moreover,	   the	   fact	   that	  
endoglin	   is	   positively	   associated	   with	   EC	   proliferation	   (while	   weakly	   expressed	   in	  
quiescent	  endothelium)	  has	   focused	   the	   interest	  on	  endoglin	   as	   a	  potential	   target	  
for	  cancer	  in	  vivo.	  
	  
1.4.2.1. Clinical	  relevance	  of	  endoglin	  in	  cancer	  
	  
Endoglin	   positive	   intratumoral	   microvascular	   density	   strongly	   correlates	   with	   poor	  
prognosis	   in	   cancer,	   being	   associated	  with	   shorter	   survival	   and	   relapse-­‐free	   survival	  
rates	   (185,	  193).	  Moreover,	   subcutaneous	   tumor	  neovascularization	  and	  growth	  are	  
impaired	   in	   endoglin	   heterozygous	   mice,	   reiterating	   the	   relevance	   of	   endoglin	   in	  
tumor	  angiogenesis	   (194).	  An	  extensive	  body	  of	   literature	  highlights	  the	  potential	  of	  
endoglin	  as	  a	  tumor	  vessel	  marker	  in	  preclinical	  and	  clinical	  studies	  (193,	  195-­‐197).	  To	  
this	  respect,	  endoglin	  can	  be	  a	  more	  specific	  marker	  for	  new,	  immature	  tumor	  vessels,	  
unlike	  other	  EC	  markers,	  widely	  expressed	  in	  both	  mature	  and	  immature	  vessels	  (198).	  	  
High	   levels	   of	   endoglin	   expression	   have,	   therefore,	   been	   confirmed	   in	   several	  
experimental	   models	   of	   breast,	   prostate	   and	   colorectal	   cancer	   (CRC)	   (198-­‐200).	  
Accordingly,	  endoglin	  is	  moderately	  expressed	  in	  most	  malignant	  tissues,	  with	  strong	  
staining	   in	   liver	   cancers	   and	   in	   several	   cases	   of	   colorectal,	   stomach	   and	   pancreatic	  
cancers	  (www.proteinatlas.org).	  
Endoglin	  expression	  has	  also	  been	  associated	  with	  predisposition	  of	  colorectal	  mucosa	  
dysplastic	  tissue	  evolution	  into	  fully	  developed	  carcinomas	  (200).	   In	  prostate	  cancer,	  
endoglin	   positive	  microvessel	   density	   correlates	  with	  Gleason	   score,	  metastasis	   and	  
tumor	   stage	   (199).	   Paradoxically,	   the	   same	   study	   indicated	   that	   endoglin-­‐positive	  
vessels	   were	  more	   poorly	   covered	   by	  α-­‐smooth	  muscle	   actin	   (αSMA)-­‐positive	   cells	  
and	   correlated	   with	   survival.	   This	   observation	   strongly	   corroborates	   our	   studies,	  
where	  endoglin	  depletion	  triggers	  EndMT	  with	  loss	  of	  the	  vascular	  marker	  CD31	  and	  
concurrent	   gain	   of	   the	  mesenchymal	  marker	  αSMA	   (Anderberg,	   Cunha,	   Zhai	   et	   al.,	  
under	   revision).	   Another	   study	   on	   CRC	   patients	   reported	   that	   microvessel	   density	  
evaluated	   by	   endoglin	   staining	   is	   significantly	   associated	  with	   survival.	   Additionally,	  
other	   reports	   connect	   loss	   of	   endoglin	   with	   prostate	   cancer	   progression	   and	  
aggressiveness	   (201)	   and	   endoglin	   presence	   with	   decrease	   in	   prostate	   tumor	   cell	  
motility	  (202).	  Our	  own	  work	  strengthens	  the	  vascular	  role	  of	  endoglin	  as	  protective	  
against	  tumor	  cell	  metastatic	  seeding	  (Anderberg,	  Cunha,	  Zhai	  et	  al.,	  under	  revision).	  
Endoglin	  exists	   in	  the	  body	  in	  two	  different	  forms:	  membrane-­‐bound	  and	  circulating	  
(185).	   Levels	  of	   soluble	  endoglin	  have	  been	   reported	   in	  plasma	  of	  pregnant	  women	  
suffering	   from	   preeclampsia	   (203)	   and	   also	   in	   patients	   suffering	   from	   colorectal,	  
breast,	  prostate	  and	   leukemic	  cancers,	  correlating	  positively	  with	  metastatic	  disease	  
(204-­‐208).	  However,	  the	  role	  of	  soluble	  endoglin	  in	  cancer	  is	  poorly	  understood.	  Since	  
soluble	   endoglin	   contains	   a	   binding	   site	   for	   different	   ligands	   of	   the	   TGF-­‐β	   family,	   it	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may	  act	  as	  a	  scavenger	  of	  circulating	  ligands,	  preventing	  their	  binding	  to	  the	  functional	  
receptors,	   hence	   interfering	   with	   vascular	   function	   and	   angiogenesis	   (209).	   An	  
intriguing	   question	   concerns	   the	   source	   of	   soluble	   endoglin	   detected	   in	   cancer	  
patients.	   Since	   endoglin	   levels	   are	   higher	   in	   tumor	   vessels,	   soluble	   endoglin	   may	  
conceivably	  derive	  from	  shedding	  by	  tumor	  ECs	  and,	  importantly,	  it	  may	  represent	  a	  
surrogate	  marker	  of	  angiogenic	  activity	  (210).	  	  
	  
1.4.2.2. Inhibitory	  biological	  agents	  targeting	  endoglin	  
	  
TRC105	  
The	  potential	  of	  endoglin-­‐targeting	  monoclonal	  antibodies	  to	  be	  used	  as	  a	  therapeutic	  
antiangiogenic	   strategy	   in	   human	   cancer	   has	   received	   considerable	   support	   from	  
preclinical	  studies.	  	  
Intravenous	   systemic	   administration	   of	   anti-­‐endoglin	   monoclonal	   antibody	   TRC105	  
was	   shown	   to	   suppress	   angiogenesis,	   tumor	   growth	   and	   metastasis	   without	   overt	  
toxicity	   in	  mice	   (207,	   211-­‐213).	   This	   antibody	   is	   robustly	   taken	  up	  by	   the	   tumor,	   as	  
compared	  to	  other	  organs,	  in	  the	  4T1	  breast	  cancer	  model	  (214).	  The	  combination	  of	  
an	  endoglin-­‐targeting	  antibody	  with	  cyclophosphamide	  and	  doxorubicin	  was	  reported	  
to	   exhibit	   synergistic	   antitumor	   efficacy	   in	   human	   skin/SCID	   mouse	   chimeras,	  
including	  in	  metronomic	  regimens	  (215,	  216).	  	  
A	   total	   of	   50	   patients	   with	   advanced	   refractory	   solid	   tumors	   were	   included	   in	   a	  
TRC105	   phase	   I	   clinical	   trial	   (212).	   Doses	   up	   to	   10	   or	   15	  mg/kg	  were	   administered	  
every	   week	   or	   every	   other	   week,	   respectively,	   to	   assess	   efficacy,	   toxicity	   and	  
tolerability	  of	  TRC105.	  Common	  adverse	  events	   included	  anemia,	  telangiectasis,	  and	  
infusion	   reactions,	   which	   reflect	   the	   mechanism	   of	   action	   of	   the	   antibody.	   Stable	  
disease	  or	  response	  was	  observed	  in	  21	  out	  of	  45	  evaluated	  patients	  (47%),	  including	  
two	  ongoing	  responses	  after	  48	  and	  18	  months	  (217).	  	  
A	   phase	   I	   clinical	   trial	   has	   been	   initiated	   with	   breast	  metastatic	   cancer	   patients	   to	  
determine	  MTD	  of	  TRC105	  in	  combination	  with	  capecitabine,	  a	  DNA	  synthesis	  blocking	  
agent,	   approved	  by	   the	  FDA	  as	   adjuvant	   treatment	   for	   colon	   cancer,	   as	  well	   as,	   for	  
CRC	  and	  metastatic	  breast	  cancer	  (www.clinicaltrials.gov).	  
	  
Endoglin-­‐Fc	  
More	  recently,	  Acceleron	  Pharma	  characterized	  a	  soluble	  mouse	  and	  human	  endoglin	  
extracellular	  domain	  fused	  to	  an	  immunoglobulin	  Fc	  domain	  (human	  endoglin	  amino	  
acid	   sequence	   26–359).	   This	   endoglin	   ligand	   trap	   binds	   specifically	   and	   with	   high	  
affinity	  to	  BMP9	  and	  BMP10	   in	  vitro.	  This	  agent	  significantly	   impaired	  VEGF-­‐induced	  
CAM	  assay	   in	  vivo.	  Finally,	  murine	  soluble	  endoglin	  extracellular	  domain	  acted	  as	  an	  
antiangiogenic	   factor	   decreasing	   blood	   vessel	   sprouting	   in	   VEGF/FGF-­‐induced	  
angiogenesis	  in	  in	  vivo	  angioreactors	  and	  tumor	  burden	  in	  the	  colon-­‐26	  mouse	  tumor	  
model	  (218).	  Together	  these	  findings	  indicate	  an	  important	  role	  for	  soluble	  endoglin	  in	  
the	  regulation	  of	  angiogenesis	  and	  evoke	  the	  prospective	  efficacy	  of	  endoglin-­‐Fc	  as	  an	  
antiangiogenic	   therapeutic	   agent.	   However,	   since	   this	   inhibitor	   binds	   to	   BMP9	   and	  
BMP10,	  rather	  then	  interfering	  directly	  with	  endoglin	  physiology,	  it	  may	  be	  difficult	  to	  
discern	  between	  the	  benefit	  of	  using	  an	  ALK1-­‐Fc	  or	  an	  Eng-­‐Fc	  soluble	  inhibitors.	  
	  
	  	  22	  
1.4.2.3. Possible	  side	  effects	  of	  targeting	  endoglin	  
	  
Similarly	  to	  ALK1	  inhibition,	  the	  appearance	  of	  telangiectasis	  upon	  endoglin	  inhibition	  
represents	   a	   surrogate	   marker	   for	   assessing	   on-­‐target	   effect.	   Interestingly,	   TRC105	  
induced	  telangiectasis	  in	  one	  patient	  during	  phase	  I	  clinical	  trial	  (217).	  
Based	   on	   a	   recent	   study,	   a	   careful	   follow-­‐up	   of	   the	   patients	   treated	  with	   endoglin	  
targeting	  molecules	  should	  be	  carried	  out.	  Our	  preclinical	  studies	  using	  mouse	  models	  
where	  endoglin	  was	  genetically	   suppressed	   indicated	  the	  emergence	  of	  a	   refractory	  
behavior	   and	   worsened	   phenotypes	   leading	   ultimately	   to	   increased	   metastatic	  
seeding	  (Anderberg,	  Cunha,	  Zhai	  et	  al.,	  under	  revision).	  	  
How	  the	  novel	  results	  associating	  endoglin	  inhibition	  with	  a	  poorer	  prognosis	  and	  the	  
beneficial	   effect	   of	   using	   a	   monoclonal	   antibody	   targeting	   endoglin	   for	   cancer	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2. AIMS	  
	  
Given	   the	   moderate	   therapeutic	   benefit	   in	   the	   clinic	   and	   reports	   of	   resistance	  
acquisition	  by	  the	  use	  of	  VEGFR	  signaling	   inhibitors	   in	  preclinical	  studies,	   the	  overall	  
aim	   of	   this	   thesis	   was	   to	   investigate	   the	   TGF-­‐β	   pathway	   for	   possible	   novel	   and	  
alternative	  antiangiogenic	  targets	  for	  anticancer	  use.	  
	  
Specifically,	  the	  aims	  of	  this	  thesis	  were:	  
	  
• to	  study	  the	  effect	  of	  ALK1	  impairment	  in	  the	  angiogenic	  switch	  and	  in	  tumor	  
development	  
• to	   investigate	   the	   potential	   of	   ALK1	   pharmacological	   inhibition	   as	   an	  
alternative	  to	  other	  antiangiogenic	  therapies	  
• to	  study	  how	  genetic	  suppression	  of	  endoglin	  affects	  the	  tumor	  vasculature	  
and	  tumor	  burden	  












Figure	  5.	  Paracrine	  signaling	  circuitry	  between	  the	  TGF-­‐β	  family	  receptors	  predominantly	  expressed	  by	  
the	   tumor	   endothelial	   cells	   (ALK1	   and	   endoglin)	   and	   the	   ligands	   (BMP9	   and	   TGF-­‐β)	   secreted	   by	   the	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3. RESULTS	  
3.1. Article	   I	   –	   Genetic	   and	   pharmacological	   targeting	   of	   activin	   receptor-­‐like	  
kinase	  1	  impairs	  tumor	  growth	  and	  angiogenesis	  
Taking	  into	  account	  that	  most	  solid	  cancers	  rely	  on	  a	  functioning	  vascular	  network	  to	  
supply	  oxygen	  and	  nutrients,	   the	   therapeutic	   strategy	  of	   interfering	  with	   the	   tumor	  
vasculature	  held	  great	  promise	  in	  the	  cancer	  field.	  
VEGF	   and	   its	   receptors	   have	   emerged	   as	   the	  most	   relevant	   angiogenesis-­‐regulating	  
pathways,	   providing	   a	   solid	   base	   for	   the	   development	   of	   antiangiogenic	   strategies	  
aiming	  at	  VEGF-­‐driven	  angiogenesis.	   Significant	  developments	   in	   this	   field,	   in	   recent	  
years,	   have	   resulted	   in	   the	   identification	   of	   a	   variety	   of	   potential	   targets	   and	   an	  
extensive	   collection	   of	   drugs,	   some	   of	  which:	   the	   anti-­‐VEGF	   antibody	   bevacizumab,	  
and	  the	  tyrosine	  kinase	  inhibitors	  sorafenib	  and	  sunitinib,	  attracted	  attention.	  Most	  of	  
these	   compounds	   have	   presented	   with	   promising	   preclinical	   tumor	   responses	   and	  
were	  approved	  by	  the	  FDA	  for	  clinical	  use	  in	  metastatic	  renal	  and	  breast	  cancers,	  CRC,	  
glioblastoma,	   non-­‐small	   cell	   lung	   carcinoma	   (NSCLC)	   and	   hepatocellular	   carcinoma	  
(219,	  220).	  	  	  
The	  inherent	  instability	  of	  tumor	  vascular	  beds	  distinct	  from	  normal	  vessels	  combined	  
with	  the	  fact	  that	  antiangiogenic	  drugs	  do	  not	  directly	  target	  the	  genetically	  unstable	  
malignant	   cells	   fueled	   the	   expectations	   on	   the	   effect	   of	   such	   drugs	   in	   tumor	  
progression.	   On	   the	   one	   hand,	   tumor	   ECs	   would	   be	   more	   prone	   to	   be	   exquisitely	  
affected	  by	  selective	  targeting	  drugs	  and	  on	  the	  other	  hand	  as	  host–derived	  “normal”	  
cells,	   the	   development	   of	   resistance	   by	   these	   ECs	   was	   thought	   to	   be	   a	   remote	  
possibility	  (11,	  221).	  	  
Despite	  all	  favorable	  indications,	  the	  scientific	  community	  has	  witnessed	  a	  suboptimal	  
outcome	  from	  antiangiogenic	  treatment	  of	  human	  cancer	  during	  the	  past	  few	  years,	  
even	   in	   combinatorial	   regimens	   with	   chemotherapeutic	   agents.	  Minimal	   success	   in	  
extending	   overall	   survival	   thus	   strongly	   suggests	   the	   need	   for	   emergence	   and	  
improvement	  of	  alternative	  therapeutic	  paths	  to	  be	  explored.	  Moreover,	  bevacizumab	  
use	   for	   metastatic	   breast	   cancer	   indication	   has	   recently	   been	   revoked,	   due	   to	   its	  
inability	  to	  improve	  therapeutic	  benefit	  in	  late	  stage	  disease.	  
The	  need	  for	  alternative	  routes	  to	  hinder	  tumorigenesis	  has	  prompted	  us	  to	  evaluate	  
the	   potential	   of	   targeting	   an	   alternative	   proangiogenic	   pathway,	   the	   TGF-­‐
β/BMP9/ALK1	   pathway.	   This	   signaling	   web	   has	   been	   long	   neglected	   until	   recently	  
despite	  all	  evidence	  for	  an	  important	  role	  in	  vascular	  development.	  
	  
Interestingly,	  examination	  of	   the	  ALK1	  messenger	  RNA	  expression	  profile	  during	   the	  
Rip1-­‐Tag2	   tumorigenic	   pathway	   demonstrated	   that	   ALK1	   presents	   with	   a	   peak	   of	  
expression	  during	  the	  onset	  of	  the	  angiogenic	  switch,	  a	  pattern	  reminiscent	  of	  that	  of	  
other	   vascular	  markers	   during	  malignant	   development.	  We	   also	   demonstrated	   that	  
ALK1	  is	  essentially	  expressed	  by	  the	  tumor	  vessels,	  while	  its	  ligands	  TGF-­‐β	  and	  BMP9	  
are	   primarily	   expressed	   by	   the	  malignant	   cell	   compartment	   in	   the	  mouse	  model	   of	  
PNETs,	  Rip1-­‐Tag2	  (222).	  
Since	   the	   complete	   ALK1	   knockout	   mouse	   is	   embryonic	   lethal	   at	   midgestation,	   to	  
assess	   the	   relevance	   of	   ALK1	   signaling	   in	   tumor	   angiogenesis,	   we	   have	   analyzed	  
heterozygous	   mice	   for	   Alk1	   under	   the	   Rip1-­‐Tag2	   tumor	   model	   context	   (Rip1-­‐Tag2;	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Alk1	   +/-­‐)	   and	   their	   littermate	   controls.	   This	   analysis	   unveiled	   an	   important	   role	   for	  
ALK1	  during	  the	  angiogenic	  switch,	  concomitant	  with	  the	  formation	  of	  fewer	  mature	  
malignant	  lesions	  and	  diminished	  overall	  tumor	  burden.	  The	  impairment	  of	  the	  tumor	  
vascular	  network	  was	  additionally	  confirmed	  by	  a	  significant	  reduction	  in	  total	  CD31-­‐
positive	  vessel	  density	  and	  decreased	  vessel	  perfusion	  (FITC-­‐lectin),	  translating	  into	  a	  
weakened	  endothelium	  and	  poorer	  physiology	  of	  the	  ALK1-­‐attenuated	  tumor	  vessels.	  
Trying	   to	  assess	   the	  possibility	  of	  modulating	  ALK1	  signaling	  as	  a	   therapeutic	   tool	   in	  
the	  combat	  of	  cancer,	  we	  made	  use	  of	  an	  ALK1-­‐Fc	  fusion	  protein,	  RAP-­‐041	  (Acceleron	  
Pharma).	  The	  effect	  of	  targeting	  ALK1	  systemically	  by	  injecting	  this	  soluble	  ligand	  trap	  
intraperitoneally	   was	   analyzed.	   As	   previously	   observed	   with	   partial	   ALK1	   genetic	  
dosage	   attenuation,	   treatment	   of	   Rip1-­‐Tag2	   tumor-­‐bearing	   mice	   with	   RAP-­‐041	  
promptly	   suppressed	   tumor	   growth	   and	   progression	   in	   a	   dose-­‐dependent	   manner.	  
Intervention	  and	  regression	  trials	  with	  RAP-­‐041	  for	   two	  weeks	  at	  10	  or	  12	  weeks	  of	  
age,	   respectively,	  were	  performed	  to	   infer	  about	   the	  efficacy	  of	  RAP-­‐041	   interfering	  
with	   angiogenesis	   in	   different	   disease	   stages	   (223)	   (Figure	   6).	   An	   early	   stage	   trial	  
(typically	  10-­‐12	  weeks	  of	  age	  in	  the	  Rip1-­‐Tag2	  model)	  allows	  assessment	  on	  how	  the	  
tested	   drug	  with	   interferes	   the	   angiogenic	   switch	   and	   how	   it	   affects	   further	   tumor	  
development.	  On	  the	  other	  hand,	  a	  late	  stage	  trial	  (typically	  12-­‐14	  weeks	  of	  age	  in	  the	  
Rip1-­‐Tag2	  model)	   applied	   when	   the	   tumor	   disease	   is	   effectively	   in	   place	   with	   fully	  
grown	   hemorrhaging,	   encapsulated	   and/or	   locally	   invasive	   tumors	   permits	  
assessment	   of	   the	   drugs	   capability	   to	   not	   only	   hinder	   tumor	   progression,	   but	   to	  
further	  diminish	   tumor	  size	  and	  ultimately	   improve	  survival.	   	  Both	   therapeutic	   trials	  




Figure	  6.	   Rip1-­‐Tag2	  pancreatic	  neuroendocrine	   tumor	  model.	   In	   this	  model,	   the	   rat	   insulin	  promoter	  
drives	  the	  expression	  of	  the	  SV40	  oncogene	  in	  the	  pancreatic	  β	  cells,	  which	  leads	  to	  the	  development	  of	  
PNETs	   in	   a	   stepwise	   and	   synchronized	   fashion,	   from	   normal	   asymptomatic	   islets	   of	   Langerhans,	   to	  
hyperplastic,	  angiogenic	  and	  fully	  developed	  tumors.	  	  	  
	  
For	   both	   genetic	   and	   pharmacological	   targeting	   analysis	   we	   confirmed	   that	   ALK1	  
target	   genes	   (Id1	   and	   Id3)	  messenger	   RNA	   levels	  were	   correspondingly	   reduced,	   as	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well	  as,	  ALK5	  target	  gene	  Pai-­‐1.	  Such	  results	  suggested	  that	  not	  only	  our	  therapeutic	  
strategy	  had	  an	  on-­‐target	  effect,	  but	  it	  also	  implies	  that	  ALK1	  and	  ALK5	  are	  intimately	  
connected	  in	  the	  tumor	  angiogenic	  process	  mediated	  by	  ALK1.	  
	  
Seeking	   the	  mechanism	   to	   explain	   the	   observed	   effect,	   and	   based	   on	   progressively	  
increased	  expression	  of	  both	  TGF-­‐β	  and	  BMP9	  during	  the	  Rip1-­‐Tag2	  tumorigenesis,	  we	  
hypothesized	   that	   both	   these	   ligands	   were	   likely	   to	   hold	   a	   key	   role	   in	   tumor	  
angiogenesis.	   A	   highly	   unanticipated	   and	   controversial	   synergy	   between	   TGF-­‐β	   and	  
BMP9	   was	   disclosed.	   We	   provided	   evidence	   supporting	   that	   TGF-­‐β	   and	   BMP9	  
collective	  action	  synergistically	  augmented	  the	  EC-­‐response	  to	  proangiogenic	  stimuli,	  
such	   as	   VEGF	   and	   FGF.	  We,	   therefore,	   provide	   relevant	   data	   for	   a	   decisive	   role	   for	  
signaling	   in	   the	   tumor	   microenvironment	   by	   TGF-­‐β	   family	   members	   in	   fueling	  
angiogenesis.	  Our	  preclinical	  studies	  on	  the	  role	  of	  ALK1	   in	  tumor	  angiogenesis	   thus	  
sustain	   a	   mechanistic	   insight	   and	   a	   biological	   rationale	   for	   clinical	   development	   of	  
ALK1	   targeting	   drugs	   for	   cancer	   indications.	   Further	   studies,	   relying	   on	   differential	  
specific	   target	   gene	   activation	   by	   each	   ligand	   alone	   and	   in	   combination	   will	   reveal	  
important	  molecular	  information	  to	  more	  clearly	  understand	  the	  underlying	  molecular	  
mechanisms	  of	  this	  synergy	  favouring	  the	  angiogenic	  switch	  (Ongoing	  studies).	  
	  
As	  discussed	  earlier,	  BMP9	  also	  binds	  to	  ALK2	  in	  non-­‐EC	  cells.	  In	  the	  event	  that	  ALK2	  is	  
also	  expressed	  by	  the	  PNETs,	  the	  effect	  we	  observed	  in	  terms	  of	  tumor	  burden	  may	  
not	   be	   totally	   attributed	   to	   impairment	   of	   ALK1	   signaling	   in	   the	   tumor	   vessels	  
triggered	   by	   BMP9.	   	   Since	   we	   analyzed	   total	  mRNA	   levels	   of	   ALK1	   target	   genes	   to	  
evaluate	  on-­‐target	  effects	   in	   this	   study,	  a	  more	  detailed	   investigation	  on	   tumor	  ECs	  
should	  be	  more	  informative.	  In	  fact,	  inhibitory	  treatment	  of	  Rip1-­‐Tag2	  tumor-­‐bearing	  
mice	   with	   RAP-­‐041	   also	   diminished	   Id1	   messenger	   RNA	   expression	   in	   the	   EC	  
compartment,	   comparatively	   to	   control	   treated	   mice	   with	   isotype	   matched	   IgG	  
(personal	  observation).	  However,	  since	  we	  have	  not	  inferred	  about	  ALK2	  expression	  in	  
PNETs	   nor	   in	   the	   isolated	   vascular	   fragments,	   we	   cannot	   totally	   exclude	   that	   ALK2	  
signaling,	  triggered	  by	  BMP9	  and/or	  BMP10,	  may	  be	  also	  affected	  by	  the	  soluble	  ALK1-­‐
Fc,	   that	   predominantly	   sequesters	   these	   ligands.	   Such	   studies	   on	   ALK2	   should	  
therefore	  be	  performed,	  even	  though	  ALK2	  has	  been	  described	  to	  preferentially	  bind	  
to	  BMP7	  (224).	  
Another	  important	  aspect	  to	  further	  consider	  is	  whether	  RAP-­‐041	  is	  effectively	  binding	  
primarily	  to	  BMP9	  during	  the	  Rip1-­‐Tag2	  tumor	  progression,	  stunting	  angiogenic	  ALK1-­‐
derived	  activity.	  To	  answer	   that	  question	  we	  have	  analyzed	  BMP9	  knockout	  mice	   in	  
the	  Rip1-­‐Tag2	  tumor	  context,	  in	  order	  to	  evaluate	  the	  role	  of	  BMP9	  in	  the	  PNET	  model	  
tumorigenic	  pathway.	  Alternatively	  to	  the	  BMP10	  KO	  mice,	  BMP9-­‐KO	  mice	  are	  viable	  
and	   fertile	   (128).	  Validating	  our	  previous	   results,	  BMP9	   indeed	  plays	  a	  direct	  critical	  
role	  in	  tumor	  development	  in	  a	  dose-­‐dependent	  manner	  (personal	  observation).	  	  
Last	   but	   not	   least,	   other	   antiangiogenic	   targeting	   approaches	   while	   conveying	  
promising	  initial	  tumor	  growth	  suppression,	  tumors	  eventually	  become	  refractory	  and	  
dissemination	  of	  metastatic	  lesions	  becomes	  dramatically	  successful	  (14,	  19-­‐21,	  219).	  
ALK1	  inhibition	  studies	  should	  carefully	  assess	  the	  metastatic	  dissemination	  index,	  in	  
order	   to	   prevail	   as	  more	   advantageous	   alternative	   therapeutics.	   Analysis	   of	   hepatic	  
material	   from	   PNET-­‐tumor	   bearing	   mice	   treated	   with	   RAP-­‐041	   for	   two	   weeks	  
(between	   10	   and	   12	   weeks	   of	   age)	   did	   not	   alter	   the	   number	   of	   metastatic	   foci	  
(personal	   observation).	   These	   results	   corroborate	   previous	   studies	   associating	   Id1	  
	  	   27	  
suppression	   in	   endothelial	   progenitor	   cells	   and	   reduction	   of	   pulmonary	  
macrometastasis	  but	  maintenance	  of	  micrometastatic	   foci	   in	   a	  breast	   cancer	  model	  
(225).	  	  
Because	  tumors	  most	  frequently	  become	  refractory	  to	  antiangiogenic	  agents	  in	  long-­‐
term	   trials,	   it	   is	  mandatory	   to	   evaluate	   such	   scenario	  with	   the	  RAP-­‐041.	   Four	  week	  
long	  treatment	  of	  Rip1-­‐Tag2	  mice	  with	  the	  ALK1	  inhibitor	  RAP-­‐041	  in	  a	  regression	  trial	  
from	  12	  to	  16	  weeks	  of	  age	  renders	  sustained	  inhibition	  of	  tumor	  growth	  and	  vessel	  
formation	   (personal	   observation).	   However,	   metastatic	   dissemination	   under	   these	  
conditions	  is	  yet	  to	  be	  analyzed	  (ongoing	  studies).	  Moreover,	  a	  four-­‐week	  treatment	  
(8-­‐12	  weeks	  of	  age)	  of	  a	  transgenic	  mouse	  model	  of	  breast	  cancer	  (MMTV-­‐PyMT)	  has	  
generated	   a	   60%	   reduction	   in	   tumor	   burden	   and	   80%	   decrease	   in	   the	   number	   of	  
metastatic	  foci	  in	  the	  lungs	  (personal	  observation).	  These	  results	  strongly	  suggest	  that	  
ALK1	   inhibition	   is	   beneficial	   in	   two	   different	   tumor	   models,	   both	   by	   modulating	  
primary	   tumor	   growth	  but	  perhaps	  more	   importantly,	   by	   additionally	   counteracting	  
metastatic	  scattering.	  
	  
ALK1	   targeting	   agents	   as	   monotherapies	   have	   been	   incredibly	   successful	   so	   far.	   In	  
phase	   I	   clinical	   trials,	   Dalantercept/ACE-­‐041,	   the	   human	   counterpart	   of	   RAP-­‐041,	  
elicited	  one	  response	  in	  a	  HNSCC	  patient	  and	  6	  other	  patients	  presented	  with	  stable	  
disease.	  Extended	  cohorts	  of	  HNSCC,	  RCC	  and	  endometrial	  cancer	  are	  presently	  being	  




Main	  findings	  of	  article	  I:	  
	  
• ALK1	  signaling	  impairment	  affects	  the	  angiogenic	  switch	  and	  tumor	  growth	  
• Pharmacological	  modulation	  of	  ALK1	  physiology	  exhibits	  therapeutic	  benefit	  
in	  a	  PNET	  model	  
• TGF-­‐β	  and	  BMP9	   synergize	   to	   improve	  EC	   response	   to	  other	  proangiogenic	  
stimuli	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3.2. Article	   II	   -­‐	   Deficiency	   for	   endoglin	   in	   tumor	   vasculature	   weakens	   the	  
endothelial	  barrier	  to	  metastatic	  dissemination	  
Experimental	  preclinical	  studies	  have	  accumulated	  evidence	  for	  the	  refractoriness	  of	  
tumors	  that	  have	  been	  subjected	  to	  VEGF-­‐targeting	  drug	  treatment	  (14,	  19-­‐21,	  226).	  
There	   are	   several	   studies	   suggesting	   a	   number	   of	   mechanisms	   of	   resistance	   to	  
antiangiogenic	   therapies	   (14,	  41),	   including	  upregulation	  of	  additional	  proangiogenic	  
stimuli	  in	  response	  to	  treatment	  (19,	  227),	  enhanced	  protective	  coverage	  of	  pericytes	  
(228),	  mobilization	  of	  bone	  marrow-­‐derived	  cells	  (229)	  and	  myeloid	  progenitors	  (230).	  
Mechanistic	   insight	   into	   evasive	   or	   intrinsic	   resistance	   to	   antiangiogenic	   therapy	  
comes	  from	  recent	  experimental	  preclinical	  trials	  (226)	  and	  it	  is	  still	  unclear	  how	  these	  
evasion	  mechanisms	  arise	  and	  whether	  they	  are	  endothelium	  specific	  or	  a	  commonly	  
induced	  therapy	  effect.	  	  
	  
Up	   until	   now,	   only	   cases	   of	   acquisition	   of	   antiangiogenic	   resistance	   towards	   VEGF-­‐
targeting	  agents	  have	  been	  published.	  In	  an	  attempt	  to	  better	  characterize	  alternative	  
antiangiogenic	   targets	   we	   evaluated	   the	   contribution	   of	   endoglin	   to	   tumor	   vessel	  
formation	  and	  malignant	  development.	  Our	  study,	  however,	  unequivocally	  shows	  that	  
resistance	   to	   antiangiogenic	   treatments	   can	   also	   arise	   as	   a	   result	   of	   targeting	  
alternative	  pathways	   in	   the	   tumor-­‐associated	   vasculature.	   The	  broader	   spectrum	  of	  
the	  concept	  warrants	  caution	  and	  calls	  for	  detailed	  studies	  on	  benefits	  or	  caveats	  of	  
using	  certain	  drugs	  indiscriminately.	  	  
	  
As	   previously	   described,	   we	   confirmed	   that	   endoglin	   presents	   with	   prevailing	  
expression	  in	  the	  tumor	  in	  actively	  proliferating	  endothelium.	  Such	  an	  event	  coupled	  
with	   a	   strong	   enhancement	   of	   endoglin	   expression	   during	   the	   activation	   of	  
angiogenesis,	  clearly	  suggested	  a	  key	   involvement	  of	  endoglin	   in	  tumor	  progression.	  
By	  analyzing	  the	  role	  of	  endoglin	  during	  PNET	  formation	  in	  Rip1-­‐Tag2;	  Eng	  +/-­‐	  and	  wt	  
control	   littermates,	   it	   became	   clear	   that	   endoglin	   is	   seemingly	   needed	   for	   the	  
angiogenic	  switch	  as	  manifested	  by	  a	  clear	  reduction	   in	  the	  premalignant	  pancreatic	  
angiogenic	   lesions	   both	   at	   9	   and	   12	   weeks	   of	   age.	   The	   initial	   delay	   in	   tumor	  
progression	  due	  to	  endoglin	  absence	  was	  eventually	  compensated	  by	  generation	  of	  a	  
comparably	   functional	  vasculature	  and	  tumor	  burden	   in	  both	  endoglin	  deficient	  and	  
control	   mice.	   Even	   though	   the	   angiogenic	   insult	   did	   not	   affect	   the	   primary	   tumor	  
growth,	   the	   metastatic	   dissemination	   was	   significantly	   enhanced	   in	   mice	   with	  
endoglin	   depletion.	   These	   unexpected	   observations	   were	   also	   mirrored	   in	   breast	  
cancer	   EO771	   tumors	   and	   Lewis	   Lung	   carcinoma,	   in	   the	   endoglin	   heterozygous	   and	  
tamoxifen-­‐inducible	   EC-­‐specific	   knockout	   (EngiKOe)	   mice.	   	   Our	   results	   are	   strongly	  
corroborated	   by	   the	   enhanced	   levels	   of	   circulating	   soluble	   endoglin	   in	   metastatic	  
cancer	  patients	   (205-­‐208).	  The	   soluble	   form	  of	  endoglin	   functions,	   in	   this	   case,	  as	  a	  
systemically	   circulating	   extracellular	   domain	   of	   endoglin	   that	   binds	   to	   a	   number	   of	  
ligands.	  	  
In	   order	   to	   more	   extensively	   comprehend	   the	   events	   leading	   to	   the	   increased	  
metastatic	   scattering	   in	   the	   absence	   of	   endoglin,	   we	   were	   prompted	   to	   evaluate	  
several	   possibilities:	   is	   it	   a	   tumor	   cell	   autonomous	   effect	   translated	   in	   enhanced	  
invasive	  properties	  or	  is	  the	  endoglin-­‐deficient	  endothelium	  more	  lenient	  to	  malignant	  
cell	   shedding	   and	   homing.	   The	   tumor	   cells-­‐derived	   contribution	   was	   ruled	   out	   by	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analysis	   of	   a	   panel	   of	   prometastatic	   genes	   delivering	   no	   significant	   differences.	  	  
Careful	   analysis	  of	   tumor	   isolated	  ECs,	  however,	   revealed	  a	  pronounced	   increase	  of	  
expression	   of	   the	   EMT/EndMT-­‐related	   transcription	   factor	   Twist.	   Also,	   the	   tumor	  
vasculature	  of	  endoglin-­‐ablated	  mice	  displayed	  suppression	  and	  redistribution	  of	  the	  
vascular	  marker	   CD31	  with	   concomitant	   enhancement	   of	   the	  mesenchymal	  marker	  
αSMA.	   For	   the	   first	   time,	   the	   TGF-­‐β/ALK5-­‐induced	   cell	   plasticity	   program	  of	   EndMT	  
(231)	  has	  been	  implicated	  in	  triggering	  metastatic	  dissemination	  by	  permeabilizing	  the	  
tumor-­‐associated	   vessels	   from	   tumors	   refractory	   to	   an	   antiangiogenic	   hit.	   These	  
original	   results	   strongly	   support	   endoglin	   as	   indispensable	   for	   endothelial	   integrity,	  
whilst	  its	  absence	  facilitates	  tumor	  aberrant	  cells	  intra-­‐	  and	  extravasation	  to	  and	  from	  
the	  cardiovascular	  system.	  An	  option	  that	  should	  be	   investigated	  in	  the	  future	  relies	  
on	   the	   use	   of	   TGF-­‐β	   inhibitors	   in	   cooperation	   with	   endoglin	   suppression.	   Such	   a	  
cumulative	  effect	  would	  feasibly	  help	  revert	  the	  EndMT	  phenotype,	  as	  we	  showed	  in	  
transmigration	  assays,	  by	  sealing	  the	  “open”	  endothelial	  barrier	  triggered	  by	  endoglin	  
attenuation.	  Furthermore,	  the	  use	  of	  ALK5	  inhibitors	  would	  additionally	  impinge	  upon	  
other	   tumor	  microenvironment	   layers.	  Most	   studies	   on	   the	   role	   of	   TGF-­‐β	   in	   cancer	  
primarily	   rely	  on	  this	  cytokine	  effect	  on	  the	  cancerous	  epithelial	  cells	  and	  on	  how	   it	  
affects	   their	   cellular	   plasticity,	   more	   specifically	   through	   EMT-­‐mediated	   metastatic	  
dispersion.	   Interestingly,	   the	   majority	   of	   the	   tumor	   studies	   under	   ALK5	   signaling	  
suppressive	  conditions	  evaluated	  primary	  tumor	  growth,	  EMT	  and	  the	  net	  metastatic	  
index,	   but	   despite	   being,	   in	   those	   studies,	   only	   a	   side	   observation	   ALK5	   inhibition	  
tends	   to	   also	   negatively	   affect	   the	   tumor	   vasculature	   (232-­‐235).	   Our	   study,	   on	   the	  
contrary,	  focuses	  essentially	  on	  an	  endoglin-­‐absence-­‐derived	  shift	  of	  signaling,	  tipping	  
the	  balance	  into	  an	  intensified	  effect	  of	  TGF-­‐β	  through	  ALK5	  on	  the	  tumor	  vasculature.	  
Whether	  the	  vasculature	  leniency	  to	  tumor	  cells’	  intra-­‐	  and	  extravasation	  mediated	  by	  
TGF-­‐β	   can	   be	   prevented,	   by	   blocking	   TGF-­‐β/ALK5	   signaling	   in	   vivo	   warrants	   further	  
investigation.	   Interestingly,	   combinatorial	   inhibition	   of	   VEGFR2	   and	   CXCR4,	   an	  
important	  chemokine	  receptor	  involved	  in	  malignant	  cell	  colonization	  of	  distant	  sites	  
of	  metastasis	  through	  EMT,	  inhibited	  metastatic	  dissemination	  more	  extensively	  than	  
either	  monotherapy	  alone	  (236).	  
	  
To	   circumvent	   the	   emergence	   of	   resilience	   towards	   an	   antiangiogenic	   insult	   it	   has	  
been	   suggested	   that	   cooperative	   efforts	   of	   targeting	   additional	   pathways	   (19)	   or	  
alternative	   cellular	   components	   in	   the	   tumor	   (226),	   such	   as	   pericytes	   or	   cancer	  
associated	  fibroblasts.	  Collective	  actions	  would	  conceavably	  contribute	  to	  weaken	  the	  
rich	   tumor	  microenvironment	   and	   represent	   an	   advantage	   to	   finally	   annihilate	   the	  
malignancy.	   Given	   that	   endoglin	   ablation	   exhibits	   strong	   resemblance	   to	   VEGF	  
inhibition	   in	   terms	   of	   tumor	   relapse	   and	   adaptation	   to	   the	   absence	   of	   their	  
proangiogenic	  effect	  (Figure	  7),	  we	  sought	  to	  analyze	  the	  effect	  of	  combined	  inhibition	  
of	  both	  pathways.	   Indeed,	  concurrent	   impairment	  of	  endoglin	  and	  VEGF	  signaling	   in	  
the	   tumor-­‐forming	   endothelium	   strongly	   arrested	   tumor	   formation	   and	   sequential	  
metastatic	   scattering.	   Collectively,	   these	   results	   suggest	   a	   strategy	   to	   bypass	   the	  
evasion	   mechanisms	   of	   resistance	   induced	   independently	   by	   VEGF	   or	   endoglin	  
impairment.	  More	  importantly,	  these	  studies	  also	  evoke	  that	  the	  cumulative	  action	  of	  
multiple	   targeting	   the	   tumor	   vasculature	   is	   of	   benefit	   in	   cancer	   disease	   treatment	  
(Figure	  8).	  These	  results	  should	  of	  course	  be	  validated	  with	  pharmacological	  inhibitors	  
for	  both	  VEGFR	  signaling	  and	  endoglin.	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A	  pertinent	  question	  remains	  for	  ALK1	  and	  endoglin	  cooperative	  signaling.	  Despite	  the	  
clear	  phenotypic	  similarities	  of	  HHT	  patients	  bearing	  Alk1	  or	  endoglin	  mutations,	  the	  
similarities	  of	  phenotype	  between	  ALK1	  and	  endoglin	  complete	  knockouts	  and	  strong	  
in	  vitro	  evidence	  for	  physical	  interaction	  between	  ALK1	  and	  endoglin	  and	  their	  ligands,	  
it	  is	  also	  apparent	  that	  endoglin	  and	  ALK1	  may	  possess	  alternative	  signaling	  traits	  and	  
differential	  ways	   to	   regulate	   the	   endothelium.	   This	   is	   evident	   at	   least	   in	   our	   tumor	  
studies,	   but	   we	   cannot	   confirm	   that	   developmental	   angiogenesis	   is	   accordingly	  
regulated.	  	  
	  
Figure	  7.	  Mechanisms	  of	   evasive	  or	   adaptive	   resistance	   to	   antiangiogenic	   therapies.	  Upon	   treatment	  
with	  antiangiogenic	  drugs	  and	  a	   transient	   tumor	  growth	   response	   to	   the	  disturbed	  endothelium,	   the	  
tumors	  manifest	  strategies	   to	  adapt	   to	   the	  debilitated	  vasculature.	  These	  strategies	  often	  encompass	  
eventual	   insensitization	   towards	   the	   drug,	   revascularization	   by	  means	   of	   upregulation	   of	   alternative	  
pathways,	  increased	  local	  invasiveness	  where	  the	  malignant	  cells	  strive	  to	  find	  alternative	  neighboring	  
vessel	  beds,	  or	  even	  enhanced	  tumor	  cells	  dissemination	  to	  distant	  sites	  of	  metastasis.	  In	  Article	  II,	  we	  
have	  for	  the	  first	  time	  added	  the	  EC	  plasticity	  mechanism	  of	  EndMT	  (that	  occurs	  as	  a	  result	  of	  endoglin	  





Main	  findings	  of	  article	  II:	  
	  
• Genetic	  stunted	  endoglin	  transiently	  affects	  the	  angiogenic	  switch	  
• Similarly	   to	   tumors	   subjected	   to	   VEGF-­‐targeting	   compounds	   genetic	  
depletion	  of	  endoglin	  renders	  tumors	  refractory	  
• By	  means	  of	  endoglin	  signaling	  impairment,	  the	  tumor	  endothelium	  becomes	  
more	  permeable	  to	  malignant	  cell	  intra-­‐	  and	  extravasation	  to	  distant	  sites	  of	  
metastasis	  
• EndMT	  is	  described	  as	  an	  adaptive	  mechanism	  to	  antiangiogenic	  strategies	  
• While	  tumor	  vessels	  become	  resilient	  to	  independent	  targeting	  of	  VEGFR	  or	  
endoglin	   signaling,	   combinatorial	   therapeutic	   targeting	   of	   both	   pathways	  
primes	  the	  endothelium	  with	  increased	  sensitivity	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4. DISCUSSION	  	  
The	  complexity	  of	  the	  TGF-­‐β	  and	  BMP	  pathways	  by	  means	  of	  redundancy,	  cooperation	  
or	   by	   simply	   having	   different	   levels	   of	   regulation	   reflects	   the	   uniqueness	   and	   tight	  
tissue-­‐specificity	  of	  this	  intriguing	  pathway.	  However,	  despite	  the	  complexity	  of	  TGF-­‐β	  
signaling,	  this	  pathway	  may	  hold	  central	  roles	  in	  tumor	  angiogenesis,	  as	  suggested	  by	  
studies	   targeting	   its	   endothelial	   specific	   receptors	   ALK1	   and	   endoglin.	   Inhibitors	   for	  
these	   receptors	   have	   already	   been	   generated	   and	   they	   hold	   great	   promise	   in	   the	  
impairment	   of	   newly	   formed	   tumor	   vessels,	   while	   leaving	   normal	   quiescent	  
vasculature	  undisturbed.	  This	  prevents	  additional	   induction	  of	  collateral	  effects	  from	  
targeting	  the	  whole	  vasculature	  within	  the	  tumor-­‐bearing	  organism.	  
The	  pleiotropy	  and	   intricacy	  of	   TGF-­‐β	   family	   signaling	   conveys	  effects	   virtually	   in	   all	  
cell	  types	   in	  the	  body.	   In	  cancerous	  disease,	   it	   is	  well	  established	  that	  TGF-­‐β	  holds	  a	  
bipolar	  role	   in	  carcinogenesis,	  acting	  as	  tumor	  suppressor	  during	  the	  initial	  stages	  of	  
tumor	   development,	   whilst	   promoting	   tumor	   growth	   and	   metastatic	   spread	   in	  
advanced	   stages	   of	   disease	   (237).	   As	   a	   consequence,	   the	   potential	   of	   using	   to	   our	  
advantage	   the	   knowledge	   on	   TGF-­‐β	   biology	   is	   still	   not	   fully	   embraced.	   The	  
development	  and	  use	  of	   inhibitors	  of	   the	  TGF-­‐β	   family	  activity	   for	   the	   treatment	  of	  
cancer	   may	   result	   in	   disparate	   effects	   depending	   on	   the	   stage	   of	   the	   disease.	  
Furthermore,	   in	   ECs,	   the	   overall	   result	   of	   signaling	   from	   TGF-­‐β	   family	   receptors	   is	  
manifold	   and	  determined	  by	   a	  plethora	  of	   factors:	   ligand	   specificity	   or	   redundancy,	  
engaged	  type	  I,	  type	  II	  receptors	  and	  coreceptors	  (95).	  In	  spite	  of	  the	  challenges	  of	  the	  
elaborated	  signaling	  network	  outcomes	  from	  the	  TGF-­‐β	  receptors	   in	   the	  various	  cell	  
types	   of	   a	   tumor,	   the	   dividends	   for	   modulating	   the	   TGF-­‐β	   critical	   network	   in	  
therapeutic	   regimens	  may	  be	   incredibly	   rewarding.	   The	   current	  preclinical	   data	   and	  
preliminary	  clinical	   results	   readily	   support	   the	   feasibility	  of	  using	  ALK1	  and	  endoglin	  
inhibitors	  as	  angiogenesis	  counteracting	  agents.	  
	  
Potential	  for	  combinatorial	  therapeutic	  studies	  
Antiangiogenic	   therapeutics	  may	  create	  a	   favorable	  environment	   for	   improved	  drug	  
delivery	   and	   priming	   the	   tumor	   microenvironment	   with	   increased	   sensitivity	   to	  
cytotoxic	  drugs	  (238).	  The	  greatest	  utility	  of	  antiangiogenic	  drugs	  is	  therefore	  unlikely	  
to	  be	  achieved	  with	  single	  agent	  strategies.	  The	  still	  scarce	  preclinical	  and	  clinical	  data	  
currently	   available	   advocate	   for	   an	   antiangiogenic	   and	   growth	   inhibitory	   effect	   of	  
attenuated	   ALK1	   signaling	   in	   cancer,	   hence	   sustaining	   the	   clinical	   development	   of	  
pharmacological	   agents	   blocking	   ALK1.	   Furthermore,	   while	   ALK1	   targeting	  
monotherapies	   have	   been	   exceptionally	   successful	   both	   in	   preclinical	   and	   clinical	  
settings,	   so	   far,	   it	   is	   reasonable	   to	  anticipate	   that	  a	   combined	   targeted	   therapy	   can	  
represent	  an	  agonistic	  effect	  in	  fighting	  cancer	  disease.	  	  
The	  multitude	  of	   cancers	  and	  heterogeneity	  within	  each	  malignancy	   combined	  with	  
case-­‐to-­‐case	  unique	  demands	  strongly	  requests	  for	  the	  incorporation	  of	  two	  or	  three	  
drugs	  with	  different	   targets	   that	  have	   independently	  been	  beneficial.	  Future	  studies	  
should	  therefore	  embark	  on	  such	  endeavors.	  Predictably,	   the	  best	  results	  may	  most	  
likely	   be	   accomplished	   in	   combinatorial	   schemes	   with	   either	   alternative	  
antiangiogenic	   drugs	   targeting	   different	   pathways,	   conventional	   chemotherapeutic	  
drugs	   or	   even	   compounds	   targeting	   additional	   cellular	   compartments	   within	   the	  
tumor	   stroma.	   Aiming	   at	   various	   niches	   in	   the	   tumor	  microenvironment	   is	   likely	   to	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capitalize	  on	  the	  benefits	  provided	  by	  principles	  of	  enhanced	  antitumor	  efficacy,	  non-­‐
overlapping	  toxicities,	  spatial	  cooperation	  of	  targeting	  different	  cellular	  categories	  and	  
last,	  but	  not	  least,	  the	  notion	  that	  the	  use	  of	  reduced	  dosages	  will	  potentially	  result	  in	  
minimized	  toxicity	  for	  the	  patient	  and	  cost	  reduction	  for	  the	  healthcare	  system.	  	  
	  
Interestingly,	  VEGF	  levels	  are	  elevated	  in	  the	  aorta,	  lungs,	  liver,	  and	  intestine	  of	  ALK1-­‐
deficient	   mice	   (90),	   suggesting	   that	   double	   targeting	   VEGFR	   and	   ALK1	   signaling	  
pathways	  may	  not	  only	  be	  the	  route	  to	  a	  more	  efficacious	  treatment	  plan,	  but	  may	  
also	   circumvent	   the	   risk	   of	   refractoriness	   to	   antiangiogenic	   drugs.	   Of	   note,	  
bevacizumab	  was	  recently	  reported	  to	  attenuate	  VEGF-­‐induced	  angiogenesis	  in	  ALK1	  
deletion-­‐induced	  vascular	  malformations	  in	  the	  adult	  mouse	  brain	  (239).	  	  
In	  a	  human/mouse	  chimera	   tumor	  model,	   targeting	  human	  ALK1	  decreased	  tumor	  
vessel	  density	  and	   improved	  antitumor	  efficacy	  when	  combined	  with	  bevacizumab	  
(156).	  This	  study	  therefore	  raised	  the	  question	  whether	  ALK1	  signaling	  may	  be	  part	  
of	   a	   set	   of	   adaptive	   mechanisms	   in	   tumors	   refractory	   to	   VEGF	   inhibition	   (156).	  
Unfortunately,	  no	  data	  have	  been	  generated	  addressing	  such	  questions.	  Moreover,	  
Dalantercept/ACE-­‐041	  used	  in	  combination	  with	  sunitinib	  impaired	  tumor	  growth	  in	  
two	  xenograft	  models	  of	  VEGF-­‐inhibitor	   resistant	  RCC,	  A498	  and	  786-­‐O	   (Acceleron	  
Pharma	   communication).	   These	   two	   models	   represent	   surrogates	   of	   RCC	   tumors	  
that	  typically	  display	  a	  transitory	  shrinkage	  upon	  VEGF	  inhibition	  but	  quickly	  restore	  
angiogenesis	   and	   resume	   the	   tumorigenic	   program,	   despite	   continuation	   of	  
treatment.	  	  In	  this	  study,	  the	  combined	  effect	  of	  Dalantercept/ACE-­‐041	  and	  sunitinib	  
prevented	  the	  restoration	  of	  tumor	  perfusion	  during	  the	  resistant	  phase	  of	  sunitinib-­‐
as	   single	   agent	   treatment	   and	   decreased	   tumor	   perfusion	   to	   a	   greater	   extent	  
(Acceleron	  Pharma	  communication).	  
None	  of	  the	  ALK1-­‐targeting	  studies	  have	  so	  far	  analyzed	  the	  potential	  adaptive	  effects	  
of	  ALK1	  targeting	  drugs	  in	  prolonged	  regimens.	  In	  order	  for	  ALK1	  inhibitors	  to	  prevail	  
as	  opposed	  to	  VEGF-­‐targeting	  drugs,	  such	  analysis	  is	  mandatory.	  
	  
Given	  the	  recent	  studies	  suggesting	  a	  regulatory	  crosstalk	   loop	  amongst	  BMP9/ALK1	  
and	   Notch	   signaling	   coordinating	   tip	   versus	   stalk	   cell	   specification,	   one	   may	  
immediately	   anticipate	   possible	   therapeutic	   benefit	   arising	   from	   a	   combinatorial	  
targeting	  of	  both	  pathways	  in	  tumor	  biology.	  
Neutralization	  of	  Dll4-­‐Notch	   signaling	   in	   tumors	   results	   in	   excessive,	  non-­‐productive	  
angiogenesis	   with	   subsequent	   inhibitory	   effects	   on	   tumor	   growth,	   due	   to	   poor	  
perfusion-­‐induced	   hypoxia	   (240,	   241).	   Furthermore,	   Dll4	   has	   been	   reported	   to	  
mediate	   tumor	   resistance	   to	  bevacizumab	   in	   vivo	   as	  a	   compensatory	  mechanism	   to	  
VEGF	   neutralization	   (242).	   Pharmacological	   targeting	   of	   Dll4/Notch	   signaling	   in	  
preclinical	  tumor	  models	  has	  been	  achieved	  by	  several	  different	  inhibitory	  strategies.	  
Specific	  targeting	  with	  anti-­‐Dll4	  antibodies	  does	  not	  induce	  overt	  toxicity	  and	  Dll4	  has	  
thus	  emerged	  as	  an	  attractive	  target	  for	  antiangiogenic	  cancer	  therapy	  (243).	  As	  Dll4	  
inhibitors	  are	  entering	  clinical	  trials	  for	  the	  treatment	  of	  solid	  malignancies,	  this	  may	  
pose	  a	  novel	  combinatorial	  therapeutic	  opportunity	  in	  breast,	  colon	  and	  renal	  cancer,	  
where	  Dll4	  is	  selectively	  expressed	  by	  the	  endothelium	  of	  malignant	  tissues	  (244-­‐246)	  
and	  where	  patients	  may	  profit	  from	  combinatorial	  actions.	  	  
	  
The	  acknowledgement	  that	  some	  tumors	  become	  refractory	  to	  antiangiogenic	  drugs	  
targeting	  VEGF	  signaling	  (19-­‐21)	  and	  our	  own	  observation	  that	  endoglin	  suppression	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enhances	  metastatic	  shedding	  (Anderberg,	  Cunha,	  Zhai	  et	  al.,	  under	  revision)	  further	  
highlights	   the	   urgency	   of	   novel	   combinatorial	   strategies.	   Once	   again,	   the	   key	   for	  
overcoming	  emergence	  of	  mechanisms	  of	  resistance	  to	  antiangiogenic	  strategies	  may	  
possibly	   be,	   as	  we	   unequivocally	   show,	   the	   combined	   inhibitory	   action	   of	   targeting	  
endoglin	   and	   VEGFR	   signaling	   simultaneously.	   The	   double	   intervention	   seems	   to	  
enable	   the	   tumors	   to	   circumvent	   acquisition	   of	   adaptive	   strategies,	   previously	  
revealed	  by	  targeting	  each	  pathway	  independently	  (Figure	  8).	  	  
The	  phase	  I	  clinical	  trial	  on	  TRC105	  evokes	  the	  combinatorial	  use	  of	  drugs	   impinging	  
their	  inhibitory	  effect	  on	  both	  endoglin	  and	  VEGFRs,	  which	  have	  shown	  to	  generate	  an	  
ameliorated	   therapeutic	   benefit	   both	   in	   the	   primary	   tumor	   burden	   but	   also	   on	  
metastatic	   dissemination.	   In	   fact,	   a	   clinical	   trial	   analyzing	   the	   effect	   of	   TRC105	   in	  
cooperation	   with	   standard-­‐dose	   bevacizumab	   in	   advanced	   solid	   tumors,	   for	   which	  
bevacizumab	  is	   indicated,	  has	  been	  launched	  (www.clinicaltrials.gov).	   Interestingly,	  a	  
study	   reported	   on	   a	   patient	   with	   HHT1	   who	   had	   a	   substantiated	   response	   to	  
bevacizumab	  (247).	  In	  this	  study,	  the	  epistaxis	  episodes	  became	  sparser	  and	  shorter.	  
In	   different	   studies,	   a	   patient	   with	   HHT1	   who	   received	   bevacizumab	   for	  malignant	  
mesothelioma	  had	  a	  dramatic	  reduction	  in	  GI	  bleeding	  from	  AVMs	  (248).	  Also,	  a	  HHT	  
patient	   with	   severe	   hepatic	   disease	   who	   received	   six	   courses	   of	   bevacizumab	   no	  
longer	   required	   liver	   transplantation	   and	   was	   well	   6	   months	   after	   completing	   the	  
treatment	   (249).	   These	   studies	   strongly	   suggest	   a	   strong	   collective	  action	  of	  double	  
targeting	   simultaneously	   endoglin	   and	   VEGF	   signaling	   to	   reacquire	   endothelial	  
homeostasis.	  Furthermore,	  studies	  in	  our	  laboratory	  provide	  evidence	  for	  an	  agonistic	  
effect	   by	   using	   endoglin	   and	   VEGFR	   targeting	   strategies	   to	   reduce	   primary	   tumor	  
burden	   and	   metastatic	   dissemination	   (Anderberg,	   Cunha	   and	   Zhai	   et	   al.,	   under	  
revision).	  
	  
An	  interesting	  question	  is	  what	  would	  happen	  in	  the	  case	  of	  targeting	  simultaneously	  
ALK1	  and	  endoglin.	  Would	  the	  adaptive	  phenotype	  exhibited	  by	  endoglin	  ablation	  be	  
even	   further	   enhanced	   or	   would	   concurrent	   inhibition	   of	   both	   receptors	   render	   a	  
phenotype	   similar	   to	   that	   observed	   with	   multitargeting	   of	   endoglin	   and	   VEGFR	  
signaling	   (Anderberg,	   Cunha,	   Zhai	   et	   al.,	   under	   revision)?	   Preliminary	   observations	  
show	   that	   ALK1	   and	   endoglin	   double	   partial	   genetic	   ablation	   (Rip1-­‐Tag2;Alk1+/-­‐;	  
Eng+/-­‐)	  results	   in	   further	  diminished	  tumor	  burden	  and	  vascularization	  compared	  to	  
Rip1-­‐Tag2;Alk1+/-­‐	   (personal	   observation),	   reminiscent	   of	   the	   results	   obtained	   by	  
integrating	   inhibitory	   insults	   upon	   endoglin	   and	   VEGFRs	   signaling.	   This	   observation	  
thus	  suggests	  once	  again	  that	  ALK1	  and	  endoglin	  may	  possess	  independent	  alternative	  
routes	   to	   impact	   on	   the	   tumor	   endothelium.	   Interestingly,	   attenuation	   of	   endoglin	  















Figure	   8.	   Resistance	   mechanisms	   to	   antiangiogenic	   therapies	   are	   not	   exclusive	   of	   VEGF-­‐targeting	  
approaches.	   Endoglin	   impairment	   also	   translates	   in	   adaptations	   that	   render	   the	   tumors	   refractory	  
(Article	  II).	  Our	  studies	  suggest	  that	  antiangiogenic	  therapies	  combined	  with	  simultaneous	  targeting	  the	  
tumor	   either	   by	   using	   other	   antiangiogenic	   drugs,	   anti-­‐metastatic,	   anti-­‐EndMT	   or	   targeting	   an	  
alternative	  cellular	  compartment	  in	  the	  tumor	  microenvironment	  permit	  to	  bypass	  evasive	  strategies	  or	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5. PERSPECTIVES	  
Cancer	   medical	   treatment	   is	   moving	   towards	   personalized	   diagnostics	   and	  
therapeutics	   that	   aggressively	   embrace	   integrative	   approaches	   (250).	   The	   greatest	  
utility	   of	   antiangiogenic	   drugs	   is	   therefore	   unlikely	   to	   be	   achieved	   with	  
monotherapeutic	  regimens.	  The	  best	  outcome	  may,	  most	  conceivably	  be	  obtained	  by	  
combinatorial	  schemes	  with	  either	  alternative	  antiangiogenic	  drugs	  targeting	  multiple	  
pathway	   circuitries,	   conventional	   standard	   of	   care	   chemotherapeutic	   drugs	   (that	  
perturb	   proliferative	   and	   survival	   processes)	   or	   even	   additive	   compounds	   targeting	  
other	   non-­‐epithelial	   cellular	   compartments	   and/or	   interactions	   within	   the	   tumor	  
malignant	  microenvironment.	  	  
Such	   combinatorial	   studies	   should	   primarily	   take	   place	   in	   preclinical	   settings	   in	  
interdisciplinary	  teams,	  in	  order	  to	  close	  the	  gap	  between	  researchers	  and	  clinicians.	  
Collaborative	   efforts	   require	   researchers	   who	   can	   make	   valuable	   contributions	   in	  
terms	  of	  treatment	  plan	  and	  predictive	  benefit,	  and	  clinicians	  who	  are	  able	  to	  make	  
educated	  choices	  of	  the	  best	  drug	  selection	  for	  their	  patients.	  As	  our	  studies	  indicate,	  
preclinical	  studies	  convey	  powerful	   information	  in	  terms	  of	  efficacy	  but	  also	  warrant	  
caution	  for	  treatment	  plans	  that	  may	  worsen	  the	  patients’	  condition.	  Optimally,	  in	  the	  
future	  we	  should	  better	  select	  the	  patients	  that	  are	  more	  prone	  to	  better	  response	  to	  
treatment	  and	  thereby	  preliminarily	  investigate	  expression	  patterns	  of	  tumor	  markers	  
in	   multiple	   cancer	   types.	   	   The	   improvement	   in	   patient	   selection	   will	   facilitate	   the	  
choice	  of	  one	  drug	  or	  a	  combinatorial	  regimen	  in	  detriment	  of	  another.	  Such	  amended	  
diagnostic	  and	  prognostic	  tools	  and	  treatment	  plan	  decision	  strategies	  in	  personalized	  
cancer	  therapy	  will	  eventually	  meet	  the	  patient-­‐tailored	  treatment	  platforms	  that	  can	  
in	   the	   future	   provide	   significant	   improvement	   of	   patient	   care,	   treatment	   efficacy,	  
drug-­‐dose	   reduction,	   toxicity	  minimization	   and	   shrinkage	   of	   health	   care	   costs	   (251-­‐
253).	  	  
In	   that	   sense,	  our	   studies	   strongly	   contributed	   to	  bringing	   the	  TGF-­‐β	   superfamily	   to	  
the	   antiangiogenic	   stage.	   Despite	   substantial	   evidence	   for	   a	   preponderant	   role	   in	  
angiogenesis,	  this	  family	  has	  a	  long	  neglected	  therapeutic	  potential.	  For	  the	  first	  time,	  
our	  studies	  unveiled	  ALK1	  as	  an	  encouraging	  novel	  target	  in	  cancer	  treatment	  (Article	  
I),	  which	   provide	   consistent	   scientific	   support	   for	   clinical	   trial	   development.	   In	   fact,	  
clinical	   trials	   on	   Dalantercept/ACE-­‐041	   have	   been	   progressing	   through	   a	   successful	  
phase	  I	  clinical	  trial	  in	  patients	  with	  solid	  tumors	  or	  refractory	  multiple	  myeloma	  and	  
subsequent	  phase	  II	  trials	  in	  expanded	  cohorts	  of	  HNSCC,	  RCC	  and	  endometrial	  cancer	  
patients.	   After	   our	   pioneering	   work,	   a	   whole	   new	   avenue	   of	   research	   has	   been	  
initiated	  and	  conducted	  to	  deepen	  the	  knowledge	  on	  ALK1	  and	  BMP9	  roles	  in	  vascular	  
biology.	  	  
	  
The	   use	   of	   proper	   preclinical	   models	   is	   also	   of	   utmost	   importance.	   Initially,	  
monotherapeutic	  and	  combinatorial	  schemes	  should	  be	  tested	   in	  preclinical	  settings	  
with	   transgenic	   mouse	   models	   that	   recapitulate	   the	   disease	   in	   its	   rightful	  
microenvironment	  and	  therefore	  mimic	  changes	  in	  the	  multitude	  of	  cell	  types	  in	  the	  
tumor.	  In	  a	  follow-­‐up	  phase,	  the	  future	  of	  drug	  testing	  should	  rely	  on	  human	  patient-­‐
derived	   tumor	   xenografts	   (PDX)	   (6,	   254).	   The	   PDX	   strategy	   opens	   a	   variety	   of	  
possibilities	   in	   terms	   of	   therapeutics	   that	   can	   be	   simultaneously	   be	   tested	   in	  mice,	  
having	  the	  advantage	  of	  having	  the	  graft	  mirroring	  the	  original	  tumor	  pathology	  and	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progression.	   Moreover,	   the	   use	   of	   cancer	   patient	   surgical	   resections	   conveys	   the	  
possibility	   to	   more	   accurately	   evaluate	   disease	   outcomes	   and	   response	   to	   various	  
therapeutic	  cocktails.	  This	  strategy	  prevents	  the	  unnecessary	  subjection	  of	  patients	  to	  
a	  myriad	  of	  drugs,	  from	  which	  they	  may	  not	  benefit	  from	  and	  in	  addition	  may	  worsen	  
their	  condition	  by	  means	  of	  increased	  toxicity	  levels	  or	  cumulative	  acquisition	  of	  drug	  
resistance.	  	  
A	   good	   example	   of	   the	   risks	   associated	   with	   assuming	   that	   a	   certain	   therapeutic	  
approach	   can	   be	   beneficial,	   is	   the	   fact	   that	   even	   though	   according	   to	   present	  
knowledge	  ALK1	  and	  endoglin	  are	   tightly	   interconnected,	  and	  targeting	   them	  would	  
expectedly	  generate	  similar	  results,	  our	  data	  suggest	  that	  endoglin	  and	  ALK1	  possibly	  
possess	   alternative	   signaling	   routes	   and	   mechanisms	   of	   EC	   homeostasis	   regulation	  
(Article	   II).	   In	   Article	   II,	   we	   have	   also	   described	   for	   the	   first	   time	   the	   EC	   plasticity	  
mechanism	   of	   EndMT	   as	   an	   adaptive	   mechanism	   to	   circumvent	   an	   antiangiogenic	  
infliction.	  Our	  studies	  show	  that	  EndMT	  occurs	  in	  the	  tumor	  endothelium	  as	  a	  result	  of	  
endoglin	  impairment,	  which	  ultimately	  favors	  malignant	  cell	  systemic	  scattering.	  This	  
observation	   opens	   a	   new	   avenue	   of	   research	   contemplating	   the	   future	   of	  
collaborative	  effect	  of	  antiangiogenic	  therapies	  with	  anti-­‐EndMT	  drugs.	  
Furthermore,	  our	  study	  also	  suggests	  a	  strategy	  to	  overcome	  adaptive	  mechanisms	  to	  
antiangiogenic	   therapies	   by	   applying	   integrative	   approaches	   of	   inhibiting	   two	  
alternative	   antiangiogenic	   relevant	   pathways	   (Article	   II).	   This	   observation	   further	  
demonstrates	   that	  while	   antiangiogenic	   drugs	   that	   as	   single	   agents	   induce	   adaptive	  
resistance,	  collaborative	  concurrent	  action	  of	  such	  drugs	  can	  reach	  impressive	  results	  
in	  tumor	  growth	  blockade	  and	  interfere	  with	  systemic	  disease	  dissemination.	  
Further	  data	  arising	  from	  the	  clinical	  trials	  on	  ALK1	  and	  endoglin	  inhibitors	  will	  provide	  
additional	   evidence	   on	   the	   benefit	   of	   using	   alternative	   routes	   to	   affect	   the	   tumor	  
endothelium	  other	  than	  primarily	  impacting	  VEGF	  pathways.	  More	  insight	  is	  necessary	  
to	   more	   thoroughly	   understand	   the	   TGF-­‐β	   pathway	   and	   its	   relevance	   in	   vascular	  
biology	  in	  order	  to	  validate	  its	  true	  potential	  as	  an	  additional,	  complimentary	  or	  even	  
alternative	  tool	  in	  the	  combat	  of	  cancer	  disease.	  
Increasing	  knowledge	  regarding	  new	  therapeutic	  strategies	  to	  extinguish	  primary	  and	  
metastatic	  disease,	  explanations	  on	  how	  tumors	  manoeuver	  to	  become	  insensitive	  to	  
therapy	   and	   the	   use	   of	   multitargeting	   regimens	   will	   eventually	   improve	   clinical	  
translatability	  of	  the	  experimental	  preclinical	  data.	  As	  a	  result,	  cancer	  treatment	  and	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In	  this	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  I	  would	  like	  to	  acknowledge	  those	  who	  directly	  or	  indirectly	  helped	  me	  thrive	  through	  my	  
last	  10	  years	  in	  science.	  The	  defence	  of	  this	  thesis	  symbolizes	  to	  me	  the	  culminating	  event	  of	  many	  steps	  
during	  my	  somewhat	  unusual	  scientific	  path.	  All	  steps,	  some	  better	  than	  others,	  made	  me	  the	  scientist	  
and	  person	  I	  am	  today.	  And	  I	  owe	  it	  to	  you	  ALL.	  
	  
First	  of	  all,	  I	  must	  thank	  Kristian	  Pietras.	  Kristian,	  you	  hosted	  me	  in	  your	  lab	  and	  deposited	  in	  me	  a	  great	  
deal	  of	  trust	  since	  the	  very	  beginning.	  You	  have	  been	  a	  mentor,	  a	  supervisor,	  a	  role	  model,	  and	  a	  friend	  
to	  me.	  It	  has	  been	  an	  honour	  to	  work	  with	  you	  for	  the	  past	  5	  years.	  I	  have	  been	  greatly	  inspired	  by	  you	  
and	  with	  the	  way	  you	  run	  your	  team.	   I	  hope	  I	  have	   learned	  enough	  to	  one	  day	  become	  as	  good	  of	  a	  
supervisor	   as	   you	   are	   (It´s	   gonna	   be	   hard	   to	   compete	   with	   the	   “Best	   Boss”!	  ).	   I	   have	   particularly	  
appreciated	  how	  you	  always	  gave	  me	  space	  to	  grow	  up	  and	  evolve	  as	  a	  scientist	  with	  my	  own	  ideas.	  
Together	  we	  have	  been	  a	  strong	  team,	  even	  when	  we	  didn't	  exactly	  share	  the	  same	  opinion	  but	  you	  
were	  always	  there	  especially	  when	  I	  needed	  help	  or	  motivation.	  It	  is	  time	  though	  for	  me	  to	  step	  out	  of	  
the	  nest	  and	  fly	  with	  my	  own	  wings	  .	  
	  
Ulf	  Eriksson,	  my	  co-­‐supervisor.	  Not	  that	  you	  ever	  co-­‐supervised	  me	  but	  I	  thank	  you	  for	  your	  friendship	  
and	   how	   you	   always	  made	  me	   feel	   as	   part	   of	   your	   group,	   for	   the	   fun	   lunch	   discussions	   and	   the	   all	  
conferences	  we	  participated	  together	  abroad	  (Paris,	  Helsinki,	  LA	  and	  Snow	  Bird).	  	  
	  
Jonas	   Fuxe,	   another	   co-­‐supervisor	   that	   didn't	   really	   co-­‐supervise	  me.	   Anyway,	   we	   share	   a	   common	  
interest:	  TGF-­‐β!	  And	  it´s	  fun	  to	  have	  you	  around!	  
	  
Calle,	   the	   matchmaker,	   you	   put	   me	   in	   contact	   with	   Kristian,	   and	   initiated	   a	   strong	   productive	   and	  
friendly	  supervisor-­‐PhD	  student	  relationship.	   I	  will	  never	  find	  the	  right	  way	  to	  say	  thank	  you	  and	  how	  
much	  I	  appreciate	  your	  help	  with	  my	  career.	  You	  are	  a	  great	  inspiration	  for	  us	  all	  scientists	  and	  TGF-­‐β	  
aficcionados.	  	  
	  
Pietras	  group	  –	  the	  original	  4	  KP	  girls	  Lotta,	  Marcela,	  Pernilla	  and	  me.	  Lotta,	   it	  was	  really	  fun	  to	  work	  
together	  you,	  our	  loooong	  days	  in	  the	  animal	  facility	  were	  never	  boring.	  You	  played	  a	  big	  part	  of	  my	  PhD	  
student	   life	   in	   the	   lab,	  outside	   the	   lab	  and	   in	  conferences.	  We	  were	  definitely	  a	  great	  and	  successful	  
research	  team!	  I´m	  glad	  I	  started	  in	  the	  lab	  together	  with	  you	  and	  that	  we	  will	  finish	  together	  as	  well.	  
And	  on	  top	  of	  everything,	  you	  never	  gave	  up	  on	  my	  Swedish!	  Pernilla,	  you	  are	  like	  a	  big	  sister	  to	  me!	  We	  
share	  a	  similar	  mindset	  in	  science,	  in	  life	  and	  in	  partying	  ;),	  it	  has	  been	  great	  to	  have	  you	  around	  with	  
your	  contagiating	  energy,	  kindness	  and	  enthusiasm.	  I´m	  sure	  you	  will	  become	  the	  best	  medical	  doctor	  
ever!	  Marcela,	  you	  are	  no	  longer	  amongst	  us	  in	  the	  lab	  but	  you	  have	  had	  a	  central	  role	  in	  the	  group.	  I	  
have	  learned	  so	  much	  with	  you	  and	  miss	  our	  discussions	  a	  lot.	  Michael	  B.,	  the	  first	  boy	  in	  the	  group,	  you	  
work	  as	  hard	  as	  you	  party!	  I	  miss	  working	  in	  the	  animal	  facility	  inspired	  by	  “I´m	  on	  a	  highway	  to	  Hell!”,	  
laughing	   hard	   till	   my	   tummy	   hurt	   and	   eating	   the	   wonderful	   sweets	   you	   used	   to	   bake.	   The	   new	  
generation	  of	  Pietras	  group	  members	  Eliane	  and	  Nik,	  I	  wish	  you	  both	  good	  luck	  in	  your	  endeavours	  in	  
Lund;	  Kristian	  H.,	  it	  has	  been	  stimulating	  to	  discuss	  with	  you	  science	  and	  life	  views;	  I	  will	  remember	  the	  
advice	  you	  gave	  me.	  
	  
Eriksson	  group	  –	  Erika	  always	  happy	  and	  energetic,	  the	  division	  wouldn’t	  be	  this	  organized	  without	  you;	  
Annelie,	  super	  direct	  Annelie,	  I	  really	  cherish	  your	  presence	  in	  the	  lab	  and	  your	  laughter	  always	  makes	  
me	  smile;	  Ingrid,	  always	  very	  focused	  and	  interested	  in	  doing	  good	  science	  –	  It´s	  always	  a	  pleasure	  to	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listen	  to	  your	  presentations	  and	  “compete”	  against	  you	  ;	  Hong,	  it´s	  so	  funny	  when	  you	  “don't	  really	  
have	  much	  to	  say”	  and	  then	  keep	  talking	  for	  10	  mins!,	  Lars,	  between	  poking	  and	  interesting	  discussions	  
(and	   not	   always	   about	   the	   Smads	  )	   we	   always	   have	   a	   good	   laugh	   together,	   love	   having	   another	  
sarcastic	  person	  around!;	  Annika,	  congratulations	  on	  your	  achievements	  so	  far	  and	  good	  luck	  with	  your	  
future;	  Daniel,	  love	  the	  Italian	  vibe	  you	  brought	  to	  lab	  ,	  Sebastian,	  the	  best	  apricot	  scone	  baker…	  it´s	  
been	  a	  while	  since	  you	  last	  brought	  some	  ;	  Hanna,	  our	  “dancing	  queen”	  and	  my	  next	  desk	  neighbor	  I	  
will	  miss	  your	  awesome	  cupcakes!	  Sofia,	  our	  smiley	  animal	  expert,	  it´s	  nice	  to	  have	  you	  back!	  And	  the	  
ex-­‐group	  members	  that	  actually	  shared	  with	  me	  most	  of	  my	  time	  as	  a	  PhD	  student:	  Monika,	  Carolina,	  
Xun	  and	  Maarten.	  Monika	  we	  have	  shared	  a	  lot	  of	  scientific	  interests	  and	  I	  really	  enjoyed	  our	  late	  night	  
discussions	  in	  the	  Ludwig+KI	  that	  kept	  making	  me	  miss	  the	  bus!	  It	  was	  always	  worth	  it	  though!	  	  I	  miss	  
having	  you	  around	  but	  I´m	  sure	  you	  are	  having	  fun	  digging	  into	  the	  rhabdomyosarcoma	  world	  in	  CCK;	  
Carolina,	  another	  former	  student	  with	  whom	  I	  spent	  so	  much	  time	  in	  the	  lab,	  I	  must	  say	  I	  never	  thought	  
I	  would	  miss	  your	  extreme	  loudness	  in	  the	  corridor	  but	  I	  really	  do…	  the	  lab	  became	  a	  lot	  emptier	  after	  
you	   left!	  You	  are	  an	  amazing	  scientist	  and	  warm-­‐hearted	  and	   I	  can	  see	  nothing	   less	  than	  brilliance	   in	  
your	  future	  .	  Good	  luck	  in	  Lausanne	  and	  I´m	  looking	  forward	  to	  having	  you	  around	  again	  soon.	  Xun,	  
you	   have	   been	   my	   informatic	   guru	   and	   master	   of	   protocol	   optimization!	   What	   would	   have	   I	   done	  
without	  you	  to	  solve	  all	  my	  computer	  issues	  and	  luciferase	  experiment	  troubleshooting?	  I	  do	  hope	  you	  
will	   find	   your	   true	   passion	   in	   life.	  Maarten,	   the	   lab	   was	   never	   the	   same	   after	   you	   left…	   I	   miss	   our	  
hilarious	  conversations	  during	   lunch,	  but	   I´m	  glad	  you	   found	  your	  happy	  place!	  BTW,	  guiney	  pigs	  will	  
never	  be	  the	  same	  for	  me…	  .	  
	  
Betsholtz	  group	  –	  Christer,	   thanks	   for	  welcoming	  us	   four	  years	  ago	  and	  contributing	   to	  a	  stimulating	  
working	  environment;	  Johanna,	  your	  presence	  in	  the	  lab	  makes	  everything	  easier;	  Guillem,	  thanks	  for	  
chats,	  Evans	  Blue	  injections	  and	  career	  advice,	  I	  admire	  how	  you	  (almost)	  manage	  to	  hide	  your	  sweet	  
self	   under	   that	   cranky	   shell!;	  Konstantin,	  my	   front	   bench	  neighbor	   and	   company	  during	   night	   shifts,	  
thanks	   a	   lot	   for	   endless	  help	  with	  microscopes	  and	  hindbrain	  dissections,	   I	  will	  miss	   your	  Drosophila	  
floating	  in	  my	  solutions	  ;	  Colin,	  thanks	  for	  not	  letting	  my	  French	  die!	  You	  always	  make	  me	  laugh	  with	  
your	  witty	  comments,	   I	  hope	  the	  RT2-­‐GRP-­‐116	  project	  turns	  out	  more	  than	  a	   lot	  of	  fun	   in	  the	  animal	  
facility!;	   Jen,	   you´ve	  been	  a	   great	   friend	  at	  work	   and	  outside	  work,	   thanks	   for	   teaching	  me	   so	  much	  
about	   the	   retina	   vasculature,	   proofreading	   this	   thesis	   and	   so	  much	  more!	  Barbara,	   the	   voted	   “best	  
neighbor”,	  you	  introduced	  me	  to	  embryo	  dissection	  and	  have	  made	  my	  life	  in	  and	  out	  of	  the	  lab	  a	  lot	  
more	   fun;	  Radiosa,	   long	  hours	   in	   the	  dark	  microscope	   room	  become	  more	  bearable	  when	  we	  chat!;	  
Maarja,	  hope	  you	  are	  having	  fun	  in	  SF,	  Lwaki,	  always	  happy,	  so	  nice	  that	  you	  moved	  to	  this	  side	  of	  MBB;	  
Linda,	  it´s	  great	  to	  have	  your	  smile	  around	  again!	  Elisabeth	  R.,	  you	  are	  so	  sweet!	  My	  first	  close	  contact	  
with	  you	  was	  when	  we	  were	  both	  part	  of	  the	  “elevator	  people”;	  Michael	  V.,	  it´s	  great	  to	  have	  a	  bit	  of	  
Uppsala	  LICR	  around	  ;	  Helene,	  you	  always	  have	  the	  best	  traveling	  advice!,	  Sara	  and	  Cecilia,	  thanks	  for	  
bench	  company.	  And	  the	  old	  members	  Elisabet	  W.,	  I	  miss	  your	  wonderful	  warm	  laughter,	  but	  I´m	  glad	  
we	  still	  meet	  outside	  the	  lab;	  Maya,	  ex-­‐roomy,	  we	  never	  really	  used	  the	  “Punishment	  cup”	  money	  ;	  
Kazuhiro,	  my	  desk	  neighbor,	  cell	  culture	  buddy,	  sushi	  master…	  and	  Tokyo	  guide.	  I	  told	  you	  I	  would	  visit	  
you	  one	  day…	  and	  I	  did!	  I	  will	  never	  forget	  that	  evening	  in	  the	  pub	  under	  the	  railway	  tracks	  in	  Iidabashi,	  
Tokyo.	  It	  was	  so	  much	  fun!	  ;	  Miyuki,	  thanks	  for	  your	  immense	  kindness	  in	  the	  lab	  and	  in	  Japan,	  I	  wish	  
you	  all	  the	  best	  on	  your	  new	  challenges!	  
	  
Fuxe	  group	  –	  The	  yearly	  TGF-­‐β	  meeting	  became	  a	  lot	  more	  fun	  since	  you	  joined	  the	  TGF-­‐β	  family.	  Mei	  
Fong,	  my	  TGF-­‐β	  roomy,	  good	  luck	  with	  your	  PhD	  preparation;	  Joel,	  another	  TGF-­‐β	  enthusiast;	  Jill,	  our	  
Xmas	  party	  committee	  meetings	  were	  never	  the	  same	  without	  you!	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Lars	   Jakobsson,	   you	  are	  a	   fun	  singing	  PI,	  great	  performance	  as	  Freddie	  Mercury!	  Yi	  and	  Michael,	   it´s	  
nice	  to	  have	  you	  around.	  
	  
Björkgren	  group	  –	  Ming-­‐Mei,	  Josefin,	  Hassan	  and	  Hussein.	  You	  are	  physically	  a	  bit	  distant	  from	  us	   in	  
the	  4th	  floor,	  but	  I	  really	  enjoy	  meeting	  you	  guys	  over	  lunch	  
	  
Tryggvasson	  group	  –	  Juha,	  you	  made	  me	  realize	  I	  missed	  dancing!!	  Thanks	  for	  waking	  up	  the	  beast	  ;	  
Asi,	  we	  need	  to	  go	  out	  horseback	  riding	  again;	  Sergei	  hope	  you	  find	  time	  one	  day	  to	  teach	  me	  how	  to	  
play	  Poker	  without	  totally	  ripping	  me	  off!;	  Patricia,	  it´s	  fun	  to	  teach	  you	  Portuguese;	  Anne	  May,	  Anne-­‐
Sofie	  and	  Lotta,	  thanks	  for	  our	  pleasant	  conversations	  in	  the	  kitchen.	  
	  
The	   MBB	   adminstration:	   Johanna	   Sandelius,	   it	   has	   been	   great	   to	   be	   able	   to	   rely	   on	   you	   in	   the	  
administration	  but	  also	  in	  the	  pubs;	  Victoria	  B	  and	  Alessandra	  Nanni,	  you	  always	  made	  my	  life	  so	  easy	  
regarding	  KI	  and	  PhD	  paper	  work;	  Torbjörn,	  Chad	  and	  Svante	  thanks	  for	  all	  the	  technical	  help.	  
	  
Claudia,	  without	  you	  my	  life	  would	  have	  been	  so	  much	  tougher	  in	  the	  lab.	  	  You	  are	  an	  incredibly	  nice	  
and	   strong	   woman.	   It	   has	   been	   lovely	   to	   chat	   with	   you	   in	   the	   corridor	   in	   our	   Portuguese/Spanish	  
conversations.	  
	  
Animal	  facility:	  Matilda,	  Pia,	  Veronica	  and	  Emelie	  –	  Thank	  you	  so	  much	  for	  your	  help	  with	  my	  mice.	  
You	  have	  been	  unbelievably	  helpful	  in	  all	  my	  studies!	  
	  
Collaborators:	  Peter	  ten	  Dijke,	  Evangelia	  Pardali,	  Marie-­‐José	  Goumans	  and	  Midori	  Thorikai	  in	  Leiden,	  
Calle	   in	  Uppsala,	  Helen	  Arthur	  and	   Zhenhua	  Zhai	   in	  Newcastle,	  Oriol	  Casanovas	   in	  Barcelona,	  Kohei	  
Miyazono	   and	   Tetsuro	  Watabe	   in	   Tokyo,	   Jasbir	   Seehra	   from	   Acceleron,	   Linda	   Lindström	   and	   Jonas	  
Bergh	  at	  KI.	  
	  
Xmas	   party	   committee	   (Carolina,	  Maarja,	   Jill,	   Jen,	   Barbara,	   Juha,	   Colin,	  Maya	   and	   Annika),	   it	   was	  
soooo	  much	  fun	  to	  organize	  the	  Vascular	  Biology	  division	  Xmas	  parties	  together	  during	  the	  last	  3	  years.	  
It	  was	  sometimes	  more	  fun	  than	  the	  actual	  party!	  	  
	  
Other	  KI	  friends:	  Bruno	  R.,	  my	  neighbor	  and	  thesis	  defence	  constant	  company	  until	  the	  end!	  you	  also	  
make	  me	  miss	  buses	  on	  the	  way	  home!!	  But	  it´s	  so	  nice	  to	  chat	  in	  Portuguese!	  Tania	  C.	  and	  Pablo,	  it´s	  
been	  super	  fun	  to	  hang	  out	  with	  you	  guys	  inside	  and	  outside	  BRECT;	  Erica	  and	  Dolores,	  the	  other	  MBB	  
ladies,	  when	  is	  the	  next	  girls	  night	  out?	  Nimesh,	  we	  no	  longer	  work	  together	  but	  we	  went	  through	  a	  lot	  
together	  and	  I	  miss	  you	  singing	  at	  the	   lab	  bench	  besides	  me	  ;	   thanks	  a	   lot	  for	  helping	  me	  plan	  and	  
organize	  my	  trip	  to	  India;	  Andreas,	  you	  were	  my	  very	  first	  student	  and	  it	  was	  such	  a	  great	  experience,	  
I´m	  glad	  you	  ended	  up	  in	  Medical	  school	  ;	  Ricardo	  C.,	  pelos	  almocos,	  desabafos	  e	  muito	  apoio;	  Tiago	  
B.,	  mais	  outro	  apoio	  no	  meu	  iniciozinho	  na	  Suecia	  
	  
The	  gang:	  Anna,	  Jen,	  Barbis,	   Jason,	  Rajesh,	  Juha,	  Colin,	  Bruno,	  Wouter	  and	   Joel.	  You	  guys	  rock!	  You	  
have	   definitely	   brought	   a	   lot	   of	   fresh	   air	   to	   my	   life	   in	   the	   past	   2-­‐3	   years.	   We	   have	   done	   so	   much	  
together,	  travelled	  together	  (Landsort,	  Riga,	  Barcelona),	  partied	  together	  and	  so	  much	  more	  (80´s	  party,	  
New	  Year´s,	   Cliff	   Barns,	   Karaoke,	  MBB,	   CMB,	  MTC,	  MF	  pubs,	   dinners,	   brunches,	   bowling,	   pool,	   trivia	  
quizzes	   on	   Sundays…)	   and	   been	   there	   for	   each	   other	   in	  many	  moments	  when	   all	  we	   needed	  was	   a	  
friend.	  A	  special	  thanks	  to	  you	  Anna	  for	  carefully	  proofreading	  this	  thesis	  and	  for	  bringing	  the	  Chemistry	  
world	  closer	  to	  me.	  You	  are	  a	  great	  friend,	  after	  all,	  we	  survived	  Krete	  without	  getting	  on	  each	  other’s	  
nerves!	  That	  should	  be	  a	  good	  sign…	  	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My	  Swedish	  mom:	   Ingela	  Frimann,	   you	  are	  a	  wonderful	  person	  with	  amazing	  strength	  and	  energy.	   I	  
have	   learned	  so	  much	  with	  you,	  and	  not	  only	  Swedish	  ,	   I	   love	  our	  discussions	  about	   life,	  work,	  art,	  
politics…	  	  You	  have	  always	  been	  a	  constant	  in	  my	  weekly	  schedule	  in	  the	  past	  5	  years	  and	  an	  amazing	  
support	  with	  whom	  I	  celebrated	  victories	  and	  released	  frustrations.	  I	  feel	  truly	  honoured	  to	  have	  you	  in	  
my	  life	  and	  I	  hope	  this	  friendship	  continues	  for	  many	  years	  to	  come.	  
	  
Uppsala	  friends:	  Jane,	  Tong	  and	  Alex,	  my	  Döbelnsgatan	  crew,	  that	  year	  we	  spent	  together	  has	  a	  very	  
special	  place	  in	  my	  heart	  and	  it	  is	  no	  wonder	  we	  are	  all	  still	  really	  good	  friends	  despite	  living	  in	  different	  
countries.	  Hele,	  Sylvie,	  Gabriela,	  Arnaud,	  Tanguy	  and	  Francesco	  –	  my	  other	  Uppsala	  gang,	  we	  have	  had	  
so	   much	   fun	   in	   Uppsala	   but	   also	   around	   Sweden	   (Abisko,	   Vendalen)	   and	   abroad	   (Lofoten,	   Åland,	  
Viljandi,	  Montpellier…).	  
	  
Kobe	  group:	  Hirashima-­‐sensei,	  Xiniy,	  Hata-­‐san,	  Moriwaki-­‐san	  and	  his	  family,	  Sano-­‐san,	  Shirakabe-­‐san	  
and	  Yuki	  –	  You	  all	  made	  my	  life	  in	  Japan	  so	  easy	  and	  fun.	  It	  was	  a	  great	  pleasure	  for	  me	  to	  become	  part	  
of	  your	  group	  and	  learn	  about	  Lymphatics	  and	  Japanese	  culture.	  I	  truly	  miss	  you	  all	  and	  the	  “oishii”	  food	  
delicacies,	  the	  izakayas,	  the	  “nomihodai”	  and	  even	  the	  karaoke!	  	  I	  also	  would	  like	  to	  thank	  Ken,	  my	  old	  
friend	  from	  the	  time	  I	  spent	  in	  GNF	  (SD)	  for	  welcoming	  me	  to	  Kobe,	  showing	  me	  around,	  and	  make	  me	  
get	  a	  different	  perspective	  in	  life.	  Taina	  and	  Esha,	  my	  international	  friends,	  it	  was	  super	  fun	  to	  have	  you	  
guys	  around	  in	  Port	  Island.	  
	  
Tokyo	  group:	  	  Kohei	  M,	  Tetsuro	  W.,	  Yasu,	  Luna,	  Tomoko,	  Aki,	  Tsubasa,	  Caname,	  Yuichi,	  Hideki,	  Mayu,	  
Tanaka-­‐san	  and	  the	  rest	  of	  the	  gang	  that	  accompanied	  me	  to	  the	  Tsukiji	  market	  at	  4h	  in	  the	  morning!!	  
Thank	  you	  all	  for	  teaching	  me	  about	  your	  TGF-­‐β	  interests,	  showing	  me	  around	  Tokyo	  and	  even	  help	  me	  
plan	   the	   rest	   of	  my	   free	   time	   in	   Japan,	   in	  Nara,	   Kyoto	   and	  Hiroshima.	   I´m	   so	   lucky	   to	   have	   had	   the	  
chance	  to	  be	  part	  of	  your	  group	  for	  2	  weeks!	  
	  
San	   Diego	   gang:	  Wei	   Li,	   my	  mentor	   and	   friend	   you	   have	   taught	  me	   so	  much	   during	  my	   9	  months	  
internship	   at	  GNF	   and	   I	   always	   get	   from	   you	   the	  most	   encouraging	   and	   supportive	   professional	   and	  
personal	  advice;	  Mario	  (Henrique	  )	  Bengtson,	  even	  busy	  you	  always	  found	  time	  and	  lots	  of	  patience	  
to	  teach	  me	  science.	  You	  are	  one	  of	  the	  most	  passionate	  researchers	  I	  have	  ever	  met!	  I´m	  happy	  your	  
hard	  work	  finally	  paid	  off!	  Claudio	  Masuda,	  Feng	  Gao,	  Claudio	  Joazeiro,	  Jeff,	  Ken,	  Orzala,	  Christopher,	  
Satchim,	  Trey	  Sato	  –	  thank	  you	  all	  for	  giving	  me	  such	  a	  fun	  time	  in	  sunny	  San	  Diego	  and	  for	  introducing	  
me	  to	  skiing	  and	  hard	  core	  hiking.	  	  
	  
Other	   scientific	   career	   friends	   that	   I	   have	   been	   collecting	   throughout	   the	   years	   in	   science:	  Memo,	  
Annamaria	  Gal,	  Ido	  Tamir,	  Peter	  Lennart	  and	  Thomas	  Waerner	  (Vienna)	  –	  you	  made	  my	  time	  in	  Vienna	  
super	  special!	  Irina,	  Teresa	  Costa,	  Rui	  Crespo,	  Ricardo	  Melo,	  Carla	  e	  Cristina,	  you	  met	  me	  really	  ate	  the	  
beginning	  of	  my	  career!	  	  
	  
University	  friends.	  Amigos	  da	  Universidade	  dos	  Acores:	  Maria	  Ana,	  Hugo	  Diogo,	  Xana	  Ramos,	  Ricardo	  
C.,	  Jorge	  Pereira,	  Ricardo	  L,	  Eva,	  Grandela,	  Nuno,	  Patricia	  Arsénio,	  Fernanda,	  Galinha,	  Maria,	  Débora,	  
Capitao	  e	  as	  minhas	  levandiscas	  Belém,	  Sónia	  C.,	  Rita	  M.	  e	  tantos	  tantos	  outros	  que	  viveram	  comigo	  
alguns	  dos	  melhores	  anos	  da	  minha	  vida,	  em	  que	  crescemos	  e	  brincamos	   juntos.	  Nao	  e	  verdade	  que	  
nao	   sei	   viver	   sem	  Ponta	  Delgada	   como	  narra	   a	  música	  dos	   Tunídeos	  mas	  PDL	  e	   S.Miguel	   hao-­‐de	   ter	  
sempre	  um	  lugar	  muito	  especial	  no	  meu	  coracao	  com	  um	  sem	  número	  de	  recordacoes	  deliciosas.	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Old	   friends.	  Amigos	  de	   longa	  data:	  Catarina,	   Joana	  C,	  Sandra	  M,	  Sónia	  B.,	  as	  minhas	  meninas…	  Love	  
you!	  You	  have	  been	  in	  my	  life	  for	  almost	  as	  long	  as	  I	  know	  myself!	  And	  it	  has	  been	  wonderful	  to	  have	  
had	  and	  still	  keep	  these	  friendships	  alive	  and	  kicking	  after	  soooo	  many	  years.	  
	  
My	  family.	  A	  minha	  famiíia.	  Quero	  agradecer-­‐te	  Mae	  por	  sempre	  teres	  acreditado	  em	  mim	  e	  teres-­‐me	  
incentivado	  a	  dar	  sempre	  o	  meu	  melhor.	  Ao	  meu	  Pai,	  que	  infelizmente	  nos	  deixou	  há	  7	  anos	  e	  que	  me	  
ensinou	  que	  a	  vida	  e	  muito	  curta	  para	  nao	  a	  aproveitarmos	  da	  melhor	  forma;	  a	   integridade	  com	  que	  
conduzo	  a	  minha	  vida	  pessoal	  e	  profissional	  foi	  sem	  dúvida	  algo	  que	  herdei	  de	  ti.	  Gostava	  muito	  que	  
estivesses	  ainda	  por	  perto	  para	  te	  ouvir	  contar	  as	  tuas	  histórias.	  O	  meu	  maninho	  Pedro,	  que	  eu	  adoro	  e	  
respeito	  muito,	   tu	   tens	   sido	  um	   forte	  pilar	  na	  minha	  vida	  pessoal;	  nem	  da	  para	  acreditar	  que	   ja	  vais	  
casar!!	  O	  nosso	  relacionamento	  nao	  comecou	  da	  melhor	  forma	  em	  criancas,	  mas	  à	  medida	  que	  fomos	  
crescendo	  foi	  fantástico	  encontrar	  tao	  perto	  um	  grande	  amigo.	  A	  minha	  irma	  Ana	  e	  os	  Cunha	  Rosa	  mais	  
pequenos,	  Lourenco	  e	  Matias,	   que	  eu	  adoro	  e	  de	  quem	  sinto	  muitas	   saudades,	   vocês	   tem-­‐me	  dado	  
muita	  alegria,	  mesmo	  quando	  me	  acordam	  as	  7h	  da	  manha	  para	  ver	  desenhos	  animados!	  
	  
And	   last	   but	   not	   least,	   Nazariy.	   You	   have	   been	   my	   friend,	   my	   partner,	   my	   confident	   and	   my	  
unconditional	   supporter.	   	   None	   of	   the	   hard	   work	   and	   papers	   would	   have	   been	   possible	   or	   worth	  
without	   you.	   You	   have	   a	  magic	   touch	   to	  make	  me	   laugh	   and	   calm	  me	   down	  when	   I´m	   stressed	   or	  
frustrated.	  Can’t	  count	  the	  times	  you	  just	  swept	  me	  of	  my	  feet	  with	  your	  immense	  patience,	  kindness,	  
analytical	  reasoning,	   intelligence	  and	  humor!	  I	  feel	  truly	  blessed	  to	  share	  my	  life	  with	  you	  and	  cannot	  
wait	  for	  many	  more	  happy	  years	  to	  come.	  Amo-­‐te!	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